Note: See section 5.

1.1.1 Abbreviations

(1) The abbreviations in Part 3 may be used to identify particular pathology services or groups of pathology services.

(2) The names of services or drugs not listed in Part 3 must be written in full.

Division 1.2—General application provisions

1.2.1 Precedence of items

(1) If a service is described:

(a) in an item in general terms; and

(b) in another item in specific terms;

only the item that describes the service in specific terms applies to the service.

(2) Subject to subclause (3), if:

(a) subclause (1) does not apply; and

(b) a service is described in 2 or more items;

only the item that provides the lower or lowest fee for the service applies to the service.

(3) If an item is expressed to include a pathology service that is described in another item, the other item does not apply to the service in addition to the first‑mentioned item, whether or not the services described in the 2 items are requested separately.

1.2.2 Circumstances in which services rendered following 2 requests to be taken to have been rendered following one request

(1) In subclause (2):

service includes assay, estimation and test.

(2) Two or more pathology services (other than services to which, under clause 1.2.3, 2.1.1 or 2.2.2, this clause does not apply) rendered for a patient following 2 or more requests are taken to have been rendered following a single request if:

(a) the services are listed in the same item; and

(b) that item is not item 74990 or 74991; and

(c) the patient’s need for the services was determined under subsection 16A(1) of the Act on the same day even if the services are rendered by an approved pathology practitioner on more than 1 day.

1.2.3 Services to which clause 1.2.2 does not apply

(1) Clause 1.2.2 does not apply to a pathology service described in subclause (2) if:

(a) under a request for a service, other than a request for a service described in paragraph (2)(a), no more than 6 tests are requested; and

(b) the tests are performed within 6 months of the request; and

(2) For subclause (1), the pathology services are:

(a) estimation of prothrombin time (INR) for a patient undergoing anticoagulant therapy; and

(b) quantitative estimation of lithium for a patient undergoing lithium therapy; and

(c) a service described in item 65070 in relation to a patient undergoing chemotherapy for neoplastic disease or immunosuppressant therapy; and

(d) a service described in item 65070 in relation to
clozaril, ticlopidine hydrochloride, methotrexate, gold, sulphasalazine or penicillamine therapy of a patient; and

(e) a service described in any of items 66500 to 66512, in relation to methotrexate or leflunomide therapy of a patient; and

(f) quantitative estimation of urea, creatinine and electrolytes in relation to:

(i) cis‑platinum or cyclosporin therapy of a patient; or

(ii) chronic renal failure of a patient being treated
in a dialysis program conducted by a recognised hospital; and

(g) quantitative estimation of albumin and calcium in relation to therapy of a patient with vitamin D, its metabolites or analogues; and

(h) quantitative estimation of calcium, phosphate, magnesium, urea, creatinine and electrolytes for a cancer patient receiving bisphosphonate infusions.

1.2.4 Referral of designated tests by one pathology practitioner to another

(1) In this clause:

designated test means a pathology test relating to a patient episode that is a test of a kind mentioned in item 65150, 65175, 66650, 66695, 66711, 66722, 66785, 66800, 66812, 66819, 66825, 69384, 69494, 71089, 71153 or 77165.

(2) This clause applies if one or more designated tests are referred by a referring APP to a receiving APP in another approved pathology authority.

(3) If a referring APP has rendered one or more designated tests:

(a) the amount mentioned in item 65150, 65153, 65175, 65176, 65177, 65178, 66650, 66695, 66698, 66701, 66704, 66707, 66711, 66722, 66725, 66728, 66731, 66785, 66800, 66803, 66812, 66819, 66825, 69384, 69387, 69390, 69393, 69396, 69494, 69495, 71089, 71091, 71153, 71155, 71157, 77165, 71166 or 71167 (as the case may be) is payable for each designated test rendered by the referring APP; and

(b) subject to subclause (5), the amount mentioned in item 65158, 65181, 66652, 66697, 66715, 66724, 66790, 66805, 66817, 66821, 66827, 69401, 69498, 71092, 71156 or 71170 (as the case may be) is payable for each designated test rendered by the receiving APP.

(4) If a referring APP has not rendered a designated test:

(a) for the first designated test that is rendered by the receiving APP—the amount mentioned in item 65157, 65180, 66651, 66696, 66714, 66723, 66789, 66804, 66816, 66820, 66826, 69400, 69497, 71090, 71154 or 71169 (as the case may be) is payable; and

(b) for each subsequent designated test (if any) that is rendered by the receiving APP—subject to subclause (6), the amount mentioned in item 65158, 65181, 66652, 66697, 66715, 66724, 66790, 66805, 66817, 66821, 66827, 69401, 69498, 71092, 71156 or 71170 (as the case may be) is payable for each test rendered.

(5) For paragraph (3)(b), the maximum number of designated tests for which the fee mentioned in the relevant item is payable is as follows:

(a) for item 66652, 66715, 66790, 66817, 66821 or 66827:

(b) for item 65158, 66805, 69498 or 71092:

(d) for item 65181 or 66724:

where:

X is the number of designated tests rendered by a referring APP.

(6) For paragraph (4)(b), the maximum number of designated tests for which the fee mentioned in the relevant item is payable is as follows:

(a) for item 66652, 66715, 66790, 66817, 66821 or 66827—1;

(b) for item 65158, 66805, 69498 or 71092—2;

(d) for item 65181 or 66724—4.

(7) Items in Group P10 (Patient episode initiation) do not apply to a receiving APP in subclause (2).

1.2.5 Items not to be split

Except as stated in clause 1.2.4 the amount mentioned in an item is payable only to one approved pathology practitioner for a single patient episode.

1.2.6 Certain pathology services to be treated as one service

(1) In this clause:

general practitioner means a medical practitioner who:

(a) is not a consultant physician in any specialty; and

(b) is not a specialist in any specialty.

set of pathology services has the meaning given by subclause 1.2.7(1).

(2) If a general practitioner, participating midwife or participating nurse practitioner requests a set of pathology services, the pathology services in the set are to be treated as individual pathology services in accordance with this clause.

(3) If the fee mentioned in an item that describes any of the services in the set of pathology services is higher than the fees mentioned in the other items that describe the services in the set:

(a) the pathology service described in the first‑mentioned item is to be treated as one pathology service; and

(b) either:

(i) the pathology service in the set that is described in the item that mentions the second‑highest fee is to be treated as one pathology service; or

(ii) if 2 or more items that describe any of those services mentions the second‑highest fee—the pathology service described in the item that mentions the second‑highest fee, and has the lowest item number, is to be treated as one pathology service; and

(c) the pathology services in the set, other than the services that are to be treated as one pathology service under paragraphs (a) and (b), are to be treated as one pathology service.

(4) If the fees mentioned in 2 or more items that describe any of the services in the set of pathology services are the same, and higher than the fees mentioned in the other items that describe the services in the set:

(a) the pathology service in the set that is described in the item that mentions the highest fee, and has the lowest item number, is to be treated as one pathology service; and

(b) the pathology service in the set that is described in the item that mentions the highest fee, and has the second‑lowest item number, is to be treated as one pathology service; and

(c) the pathology services in the set, other than the services that are to be treated as one pathology service under paragraphs (a) and (b), are to be treated as one pathology service.

(5) If pathology services are to be treated as one pathology service under paragraph (3)(c) or (4)(c), the fee for the one pathology service is the highest fee mentioned in any of the items that describe the pathology services that are to be treated as the one pathology service.

1.2.7 Meaning of set of pathology services

(1) In clause 1.2.6:

set of pathology services means a group of pathology services:

(a) that consist of services that are described in at least 4 different items; and

(b) all of which are requested in a single patient episode; and

(d) none of which is referred to in item 66900, 69484, 73053 or 73055.

(2) However, a set of pathology services does not include the following items:

(a) an item in Group P10 (Patient episode initiation), Group P11 (Specimen referred), Group P12 (Management of bulk‑billed services) or Group P13 (Bulk billing incentive for episodes consisting of a P10 service);

(b) if a service is requested by an approved pathology practitioner of an approved pathology authority and rendered by another approved pathology practitioner of an approved pathology authority that is not related to the approved pathology authority of the first‑mentioned approved pathology practitioner—item 65079, 65082, 65157, 65158, 65166, 65180, 65181, 66606, 66610, 66639, 66642, 66651, 66652, 66663, 66666, 66696, 66697, 66714, 66715, 66723, 66724, 66780, 66783, 66789, 66790, 66792, 66804, 66805, 66816, 66817, 66820, 66821, 66826, 66827, 66832, 66834, 66837, 69325, 69328, 69331, 69379, 69383, 69400, 69401, 69419, 69451, 69489, 69492, 69497, 69498, 69500, 71076, 71090, 71092, 71096, 71148, 71154, 71156, 71169, 71170, 73309, 73312, 73315, 73318, 73321 or 73324.

(3) An approved pathology authority is related to another approved pathology authority for paragraph (2)(b) if:

(a) both approved pathology authorities are employed (including employed under contract) by the same person, whether or not the person is also an approved pathology authority; or

(b) either of the approved pathology authorities is employed (including employed under contract) by the other; or

(c) both approved pathology authorities are corporations and are connected entities within the meaning of the Corporations Act 2001; or

(d) the approved pathology authorities are partners (whether or not either or both of the approved pathology authorities are individuals and whether or not other persons are in partnership with either or both of the approved pathology authorities); or

(e) both approved pathology authorities are operated by the Commonwealth or an authority of the Commonwealth; or

(f) both approved pathology authorities are operated by the same State or internal Territory or an authority of the same State or internal Territory.

1.2.8 Satisfying requirements described in pathology service

Unless the contrary intention appears, a requirement contained in the description of a pathology service in Part 2 is satisfied if:

(a) for a requirement for information—the information:

(i) is included in the request for the service; or

(ii) was supplied in writing on an earlier occasion to
the approved pathology authority that rendered
the service, and has been kept by the approved pathology authority; or

(b) for a requirement for laboratory test results—the results are:

(i) included in the request for the service; or

(ii) obtained from another laboratory test performed in the same patient episode; or

(iii) included in results from an earlier laboratory test that have been kept by the approved pathology authority.

1.2.9 Application of items—services provided with autologous injections of blood or blood products

An item in the table does not apply to a service mentioned in the item if the service is provided to a patient at the same time as, or in connection with, an injection of blood or a blood product that is autologous.

Part 2—Services and fees

Division 2.1—Group P1: haematology

2.1.1 Services to which clause 1.2.2 does not apply

(1) Clause 1.2.2 does not apply to a pathology service described in item 65060, 65070, 65120, 65123, 65126, 65129, 65150, 65153 or 65156 if:

(a) the service is rendered in relation to one or more specimens taken on any of not more than 6 occasions in a period of 24 hours; and

(b) the service is rendered to an inpatient of a hospital; and

(d) the pathology provider of the service writes on the account for the service that the service has a rule 3 exemption.

(2) Clause 1.2.2 does not apply to a pathology service described in item 65109 or 65110 if:

(a) the service is rendered:

(i) for a service described in item 65109—on one of not more than 5 occasions in a period of 24 hours; and

(ii) for a service described in item 65110—on one of not more than 2 occasions in a period of 24 hours; and

(b) the service was requested on a separate occasion to any other occasions on which the service was requested in the period of 24 hours; and

2.1.2 Item taken to refer only to the first service of a particular kind

(1) For an item in Group P1 (Haematology):

(a) if pathology services of a kind mentioned in item 65090 or 65093 are rendered for a patient during a period when the patient is in hospital, the item applies only to the first pathology service of that kind rendered for the patient during the period; and

(b) if:

(i) tests (except tests mentioned in item 65099, 65102, 65105 or 65108) are carried out in relation to a patient episode; and

(ii) specimen material from the patient episode is stored; and

(iii) in response to a request made within 14 days of the patient episode, further tests (except tests mentioned in item 65099, 65102, 65105 or 65108) are carried out on the stored material;

the later tests and the earlier tests are taken to be part of one patient episode.

(2) Items 65102 and 65108 apply only if a minimum of 6 units are issued for a patient’s care in any 1 day.

(3) For items 65099 and 65102:

compatibility tests by crossmatch means that, in addition to all the tests mentioned in paragraphs (a) and (b) of the item, donor red cells from each unit must have been tested directly against the serum of the patient by one or more accepted crossmatching techniques.

Group P1—Haematology
Item	Pathology service	Fee ($)
65060	Haemoglobin, erythrocyte sedimentation rate, blood viscosity—one or more tests	7.85
65066	Examination of: (a) a blood film by special stains to demonstrate Heinz bodies, parasites or iron; or (b) a blood film by enzyme cytochemistry for neutrophil alkaline phosphatase, alpha‑naphthyl acetate esterase or chloroacetate esterase; or	10.40
	(c) a blood film using any other special staining methods including periodic acid Schiff and Sudan Black; or (d) a urinary sediment for haemosiderin; including a service described in item 65072
65070	Erythrocyte count, haematocrit, haemoglobin, calculation or measurement of red cell index or indices, platelet count, leucocyte count and manual or instrument generated differential count (not being a service where haemoglobin only is requested)—one or more instrument‑generated set of results from a single sample and (if performed): (a) a morphological assessment of a blood film; and (b) any service in item 65060 or 65072	16.95
65072	Examination for reticulocytes including a reticulocyte count by any method—one or more tests	10.20
65075	Haemolysis or metabolic enzymes—assessment by one or more of the following tests: (a) erythrocyte autohaemolysis test; (b) erythrocyte osmotic fragility test; (c) sugar water test; (d) G–6–PD (qualitative or quantitative) test; (e) pyruvate kinase (qualitative or quantitative) test; (f) acid haemolysis test; (g) quantitation of muramidase in serum or urine; (h) Donath Landsteiner antibody test; (i) other erythrocyte metabolic enzyme tests	51.95
65078	Tests for the diagnosis of thalassaemia consisting of haemoglobin electrophoresis or chromatography and at least 2 of: (a) examination for HbH; or (b) quantitation of HbA2; or (c) quantitation of HbF; including (if performed) any service described in item 65060 or 65070	90.20
65079	A test described in item 65078 if rendered by a receiving APP—one or more tests	90.20
65081	Tests for the investigation of haemoglobinopathy consisting of haemoglobin electrophoresis or chromatography and at least one of: (a) heat denaturation test; or (b) isopropanol precipitation test; or (c) tests for the presence of haemoglobin S; or (d) quantitation of any haemoglobin fraction (including S, C, D, E); including (if performed) any service described in item 65060, 65070 or 65078	96.60
65082	A test described in item 65081 if rendered by a receiving APP—one or more tests	96.60
65084	Bone marrow trephine biopsy—histopathological examination of sections of bone marrow and examination of aspirated material (including clot sections where necessary), including (if performed) any test described in item 65060, 65066 or 65070	165.85
65087	Bone marrow—examination of aspirated material (including clot sections where necessary), including (if performed) any test described in item 65060, 65066 or 65070	83.10
65090	Blood grouping (including back‑grouping if performed)—ABO and Rh (D antigen)	11.15
65093	Blood grouping—Rh phenotypes, Kell system, Duffy system, M and N factors or any other blood group system—one or more systems, including item 65090 (if performed)	22.00
65096	Blood grouping (including back‑grouping if performed), and examination of serum for Rh and other blood group antibodies, including: (a) identification and quantitation of any antibodies detected; and (b) (if performed) any test described in item 65060 or 65070	41.00
65099	Compatibility tests by crossmatch—all tests performed on any 1 day for up to 6 units, including: (a) all grouping checks of the patient and donor; and (b) examination for antibodies and, if necessary, identification of any antibodies detected; and (c) (if performed) any tests described in item 65060, 65070, 65090 or 65096	108.90
65102	Compatibility tests by crossmatch—all tests performed on any 1 day in excess of 6 units, including: (a) all grouping checks of the patient and donor; and (b) examination for antibodies and, if necessary, identification of any antibodies detected; and (c) (if performed) any tests described in item 65060, 65070, 65090, 65096, 65099 or 65105	164.60
65105	Compatibility testing using at least a 3 cell panel and issue of red cells for transfusion—all tests performed on any 1 day for up to 6 units, including: (a) all grouping checks of the patient and donor; and (b) examination for antibodies and, if necessary, identification of any antibodies detected; and (c) (if performed) any tests described in item 65060, 65070, 65090 or 65096	108.90
65108	Compatibility testing using at least a 3 cell panel and issue of red cells for transfusion—all tests performed on any 1 day in excess of 6 units, including: (a) all grouping checks of the patient and donor; and (b) examination for antibodies and, if necessary, identification of any antibodies detected; and (c) (if performed) any tests described in item 65060, 65070, 65090, 65096, 65099 or 65105	164.60
65109	Release of fresh frozen plasma or cryoprecipitate for the use in a patient for the correction of a coagulopathy—one release	12.90
65110	Release of compatible fresh platelets for the use in a patient for platelet support as prophylaxis to minimise bleeding or during active bleeding—one release	12.90
65111	Examination of serum for blood group antibodies (including identification and, if necessary, quantitation of any antibodies detected)	23.20
65114	One or more of the following tests: (a) direct Coombs (antiglobulin) test; (b) qualitative or quantitative test for cold agglutinins or heterophil antibodies	9.10
65117	One or more of the following tests: (a) spectroscopic examination of blood for chemically altered haemoglobins; (b) detection of methaemalbumin (Schumm’s test)	20.25
65120	Prothrombin time (including INR where appropriate), activated partial thromboplastin time, thrombin time (including test for the presence of heparin), test for factor XIII deficiency (qualitative), Echis test, Stypven test, reptilase time, fibrinogen, or one of fibrinogen degradation products, fibrin monomer or D‑dimer—one test	13.70
65123	Two tests described in item 65120	20.35
65126	Three tests described in item 65120	27.85
65129	Four or more tests described in item 65120	35.50
65137	A test for the presence of lupus anticoagulant, not being a service connected with a service to which item 65175, 65176, 65177, 65178 or 65179 applies	25.35
65142	Confirmation or clarification of an abnormal or indeterminate result of a test mentioned in item 65175, by testing a specimen collected on a different day—one or more tests	25.35
65144	Platelet aggregation in response to ADP, collagen, 5HT, ristocetin or other substances, or heparin, low molecular weight heparins, heparinoid or other drugs—one or more tests	56.55
65147	Quantitation of anti‑Xa activity when monitoring is required for a patient receiving a low molecular weight heparin or heparinoid—one test	37.90
65150	Quantitation of von Willebrand factor antigen, von Willebrand factor activity (ristocetin cofactor assay), von Willebrand factor collagen binding activity, factor II, factor V, factor VII, factor VIII, factor IX, factor X, factor XI, factor XII, factor XIII, Fletcher factor, Fitzgerald factor, circulating coagulation factor inhibitors other than by Bethesda assay—one test	70.90
65153	Two tests described in item 65150	141.85
65156	Three or more tests described in item 65150	212.75
65157	A test described in item 65150, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP—one test	70.90
65158	A test described in item 65150, if rendered by a receiving APP, where one or more tests in the item have been rendered by the referring APP—one test	70.90
65159	Quantitation of circulating coagulation factor inhibitors by Bethesda assay—one test	70.90
65162	Examination of a maternal blood film for the presence of fetal red blood cells (Kleihauer test)	10.45
65165	Detection and quantitation of fetal red blood cells in the maternal circulation by detection of red cell antigens using flow cytometric methods including (if performed) any test described in item 65070 or 65162	34.45
65166	A test described in item 65165 if rendered by a receiving APP—one or more tests	34.45
65171	A test for the presence of antithrombin III deficiency, protein C deficiency, protein S deficiency or activated protein C resistance in a first degree relative of a person who has a proven deficiency mentioned in this item—one or more tests	25.35
65175	A test for the presence of antithrombin III deficiency, protein C deficiency, protein S deficiency, lupus anticoagulant, activated protein C resistance, if the request for the test specifically identifies that the patient has a history of venous thromboembolism—quantitation by one or more techniques—one test	25.35
65176	Two tests described in item 65175	48.65
65177	Three tests described in item 65175	71.95
65178	Four tests described in item 65175	95.20
65179	Five tests described in item 65175	118.50
65180	A test described in item 65175, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP—one test	25.35
65181	A test described in item 65175, if rendered by a receiving APP, where one or more tests in the item have been rendered by the referring APP—one test	23.30

Division 2.2—Group P2: chemical

2.2.1 Creatinine ratios

A pathology service mentioned in an item in Group P2 (Chemical) (except item 66500) that:

(a) involves the measurement of a substance in urine; and

(b) requires calculation of a substance/creatinine ratio;

is taken to include the measurement of creatinine necessary for the calculation.

2.2.2 Services to which clause 1.2.2 does not apply

Clause 1.2.2 does not apply to a pathology service described in item 66500, 66503, 66506, 66509, 66512, 66584 or 66800 if:

(a) the service is rendered in relation to one or more specimens taken on any of not more than 6 occasions in a period of 24 hours; and

(b) the service is rendered to an inpatient of a hospital; and

(d) the pathology provider of the service writes on the account for the service that the service has a rule 3 exemption.

2.2.3 Limitation on certain items

(1) For any particular patient, the following items are applicable not more than twice in a 12 month period:

(a) items 66539 and 66607;

(b) item 66605, 66606 or 66610.

(2) For any particular patient, each of items 66551 and 66660 is applicable not more than 4 times in a 12 month period.

(3) For any particular patient, each of items 66554 and 66830 is applicable not more than 6 times in a 12 month period.

(4) For any particular patient, item 66626 is applicable not more than 36 times in a 12 month period.

(5) For any particular patient, item 66750 or 66751 is applicable not more than once in a pregnancy.

(6) For any particular patient, item 66517 is applicable not more than 3 times in a pregnancy.

(7) For any particular patient, item 66838 is applicable not more than once in a 12 month period.

2.2.5 Thyroid function testing

(1) For item 66719:

abnormal level of TSH means a level of TSH that is outside the normal reference range for the particular method of assay used to determine the level.

(2) Unless paragraph (a) of item 66719 is satisfied, the amount mentioned in the item is not payable for a pathology service mentioned in the item unless the pathologist who renders the service has a written statement from the medical practitioner who requested the service that satisfies subclause (3).

(3) The written statement from the medical practitioner must indicate:

(a) that the tests are required for a particular purpose, being a purpose mentioned in paragraph (b) of item 66719; or

(b) that the medical practitioner who requested the tests suspects the patient has pituitary dysfunction; or

2.2.6 Limitation on certain items

(1) For any particular patient, each of items 66655, 66659 and 66841 is applicable not more than once in a 12 month period.

(2) For any particular patient, each of items 66819, 66820, 66821, 66822, 66825, 66826, 66827 and 66828 is applicable not more than 3 times in a 6 month period.

2.2.7 Nutritional and toxicity metals testing

(1) In this clause:

metal toxicity testing group means items 66825, 66826, 66827, 66828, 66831 and 66832.

nutritional metals testing group means items 66819, 66820, 66821 and 66822.

(2) An item in the nutritional metals testing group or the metal toxicity testing group does not apply to a service performed if medicare benefits are paid or payable for tests that are performed for the same patient in 3 patient episodes requested within 6 months before the request for that service, under any of:

(a) that item; or

(b) the other item in the same group; or

Group P2—Chemical
Item	Pathology service	Fee ($)
66500	Quantitation in serum, plasma, urine or other body fluid (except amniotic fluid), by any method, except reagent tablet or reagent strip, (with or without reflectance meter) of acid phosphatase, alanine aminotransferase, albumin, alkaline phosphatase, ammonia, amylase, aspartate aminotransferase, bicarbonate, bilirubin (total), bilirubin (any fractions), C‑reactive protein, calcium (total or corrected for albumin), chloride, creatine kinase, creatinine, gamma glutamyl transferase, globulin, glucose, lactate dehydrogenase, lipase, magnesium, phosphate, potassium, sodium, total cholesterol, total protein, triglycerides, urate or urea—one test	9.70
66503	Two tests described in item 66500	11.65
66506	Three tests described in item 66500	13.65
66509	Four tests described in item 66500	15.65
66512	Five or more tests described in item 66500	17.70
66517	Quantitation of bile acids in blood in pregnancy	19.65
66518	Investigation of cardiac or skeletal muscle damage by quantitative measurement of creatine kinase isoenzymes, troponin or myoglobin in blood—tests performed on only one specimen in a 24 hour period	20.05
66519	Investigation of cardiac or skeletal muscle damage by quantitative measurement of creatine kinase isoenzymes, troponin or myoglobin in blood—tests performed on 2 or more specimens in a 24 hour period	40.15
66536	Quantitation of HDL cholesterol	11.05
66539	Electrophoresis of serum for demonstration of lipoprotein subclasses: (a) if the cholesterol is >6.5 mmol/L and triglyceride >4.0 mmol/L; or (b) in the diagnosis of types III and IV hyperlipidaemia	30.60
66542	Oral glucose tolerance test for the diagnosis of diabetes mellitus, that includes: (a) administration of glucose; and (b) at least 2 measurements of blood glucose; and (c) (if performed) any test described in item 66695	18.95
66545	Oral glucose challenge test in pregnancy for the detection of gestational diabetes that includes: (a) administration of glucose; and (b) one or 2 measurements of blood glucose; and (c) (if performed) any test in item 66695	15.80
66548	Oral glucose tolerance test in pregnancy for the diagnosis of gestational diabetes that includes: (a) administration of glucose; and (b) at least 3 measurements of blood glucose; and (c) (if performed) any test in item 66695	19.90
66551	Quantitation of glycosylated haemoglobin performed in the management of established diabetes	16.80
66554	Quantitation of glycosylated haemoglobin performed in the management of pre‑existing diabetes where the patient is pregnant—including a service in item 66551 (if performed)	16.80
66557	Quantitation of fructosamine performed in the management of established diabetes—each test to a maximum of 4 tests in a 12 month period	9.70
66560	Microalbumin—quantitation in urine	20.10
66563	Osmolality, estimation by osmometer, in serum or in urine—one or more tests	24.70
66566	Quantitation of: (a) blood gases (including pO2, oxygen saturation and pCO2); and (b) bicarbonate and pH; including any other measurement (e.g. haemoglobin, lactate, potassium or ionised calcium) or calculation performed on the same specimen—one or more tests on one specimen	33.70
66569	Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 2 specimens performed on any 1 day	42.60
66572	Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 3 specimens performed on any 1 day	51.55
66575	Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 4 specimens performed on any 1 day	60.45
66578	Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 5 specimens performed on any 1 day	69.35
66581	Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 6 or more specimens performed on any 1 day	78.25
66584	Quantitation of ionised calcium (except if performed as part of item 66566)—one test	9.70
66587	Urine acidification test for the diagnosis of renal tubular acidosis including the administration of an acid load, and pH measurements on 4 or more urine specimens and at least one blood specimen	47.55
66590	Calculus, analysis of one or more	30.60
66593	Ferritin—quantitation, except if requested as part of iron studies	18.00
66596	Iron studies, consisting of quantitation of: (a) serum iron; and (b) transferrin or iron binding capacity; and (c) ferritin	32.55
66605	Vitamins—quantitation of vitamin B1, B2, B3, B6 or C in blood, urine or other body fluid—one or more tests	30.60
66606	A test described in item 66605 if rendered by a receiving APP—one or more tests	30.60
66607	Vitamins—quantitation of vitamin A or E in blood, urine or other body fluid—one or more tests in a 6 month period	75.75
66610	A test described in item 66607 if rendered by a receiving APP—one or more tests	75.75
66623	All qualitative and quantitative tests on blood, urine or other body fluid for: (a) a drug or drugs of abuse (including illegal drugs and legally available drugs taken other than in appropriate dosage); or (b) ingested or absorbed toxic chemicals; including a service described in item 66800, 66803, 66806, 66812 or 66815 (if performed), but excluding: (c) the surveillance of sports people and athletes for performance improving substances; and (d) the monitoring of patients participating in a drug abuse treatment program	41.50
66626	Detection or quantitation or both of a drug, or drugs, of abuse or a therapeutic drug, on a sample collected from a patient participating in a drug abuse treatment program, including all tests on blood, urine or other body fluid, not including: (a) the surveillance of sports people and athletes for performance improving substances; and (b) the detection of nicotine and metabolites in smoking withdrawal programs	24.10
66629	Beta‑2‑microglobulin—quantitation in serum, urine or other body fluids—one or more tests	20.10
66632	Caeruloplasmin, haptoglobins, or prealbumin—quantitation in serum, urine or other body fluids—one or more tests	20.10
66635	Alpha‑1‑antitrypsin—quantitation in serum, urine or other body fluid—one or more tests	20.10
66638	Isoelectric focusing or similar methods for determination of alpha‑1‑antitrypsin phenotype in serum—one or more tests	49.05
66639	A test described in item 66638 if rendered by a receiving APP—one or more tests	29.20
66641	Electrophoresis of serum or other body fluid to demonstrate: (a) the isoenzymes of lactate dehydrogenase; or (b) the isoenzymes of alkaline phosphatase; including the preliminary quantitation of total relevant enzyme activity—one or more tests	29.20
66642	A test described in item 66641 if rendered by a receiving APP—one or more tests	29.20
66644	C‑1 esterase inhibitor—quantitation	20.15
66647	C‑1 esterase inhibitor—functional assay	45.10
66650	Alpha‑fetoprotein, CA‑15.3 antigen (CA15.3), CA‑19.9 antigen (CA19.9), CA‑125 antigen (C125), cancer associated serum antigen (CASA), carcinoembryonic antigen (CEA), human chorionic gonadotrophin (HCG), neuron specific enolase (NSE) thyroglobulin in serum or other body fluid, in the monitoring of malignancy or in the detection or monitoring of gestational trophoblastic disease or a hepatic or germ cell tumour—quantitation—one test	24.35
66651	A test described in item 66650, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP—one test	24.35
66652	A test described in item 66650, if rendered by a receiving APP, where one or more tests in the item have been rendered by the referring APP—one test	20.30
66653	Two or more tests described in item 66650	44.60
66655	Prostate specific antigen—quantitation	20.15
66656	Prostate specific antigen (PSA) quantitation in the monitoring of previously diagnosed prostatic disease (including a test to which item 66655 applies)	20.15
66659	Prostate specific antigen (PSA), quantitation of 2 or more fractions of PSA and any derived index, including, if performed, a test described in item 66656, in the follow up of a PSA result that lies at or above the age‑related median but below the age‑related, method‑specific 97.5% reference limit	37.30
66660	Prostate specific antigen (PSA), quantitation of 2 or more fractions of PSA and any derived index, including, if performed, a test described in item 66656, in the follow up of a PSA result that lies at or above the age‑related, method‑specific 97.5% reference limit, but below 10 µg/L	37.30
66662	Quantitation of hormone receptors on proven primary breast or ovarian carcinoma or a metastasis from a breast or ovarian carcinoma or a subsequent lesion in the breast—one or more tests	79.95
66663	A test described in item 66662 if rendered by a receiving APP—one or more tests	79.95
66665	Lead quantitation in blood or urine (other than for occupational health screening purposes) to a maximum of 3 tests in a 6 month period—each test	30.60
66666	A test described in item 66665 if rendered by a receiving APP—one or more tests	30.60
66667	Quantitation of serum zinc in a patient receiving intravenous alimentation—each test	30.60
66671	Quantitation of serum aluminium in a patient in a renal dialysis program—each test	36.90
66674	Quantitation of: (a) faecal fat; or (b) breath hydrogen in response to loading with disaccharides; one or more tests within a 28 day period	39.95
66677	Test for tryptic activity in faeces in the investigation of diarrhoea of longer than 4 weeks duration in children under 6 years	11.15
66680	Quantitation of disaccharidases and other enzymes in intestinal tissue—one or more tests	74.45
66683	Enzymes—quantitation in solid tissue or tissues other than blood elements or intestinal tissue—one or more tests	74.45
66686	Performance of one or more of the following procedures: (a) growth hormone suppression by glucose loading; (b) growth hormone stimulation by exercise; (c) dexamethasone suppression test; (d) sweat collection by iontophoresis for chloride analysis; (e) pharmacological stimulation of growth hormone	50.65
66695	Quantitation in blood or urine of hormones and hormone binding proteins—ACTH, aldosterone, androstenedione, C‑peptide, calcitonin, cortisol, DHEAS, 11‑deoxycortisol, dihydrotestosterone, FSH, gastrin, glucagon, growth hormone, hydroxyprogesterone, insulin, LH, oestradiol, oestrone, progesterone, prolactin, PTH, renin, sex hormone binding globulin, somatomedin C(IGF –1), free or total testosterone, urine steroid fraction or fractions, vasoactive intestinal peptide—one test	30.50
66696	A test described in item 66695, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP	30.50
66697	A test described in item 66695, if rendered by a receiving APP, where one or more tests in the item have been rendered by the referring APP—each test to a maximum of 4 tests	13.20
66698	Two tests described in item 66695	43.70
66701	Three tests described in item 66695	56.90
66704	Four tests described in item 66695	70.15
66707	Five or more tests described in item 66695	83.35
66711	Quantitation in saliva of cortisol in: (a) the investigation of Cushing’s syndrome; or (b) the management of children with congenital adrenal hyperplasia; one test	30.15
66712	Two tests described in item 66711	43.05
66714	A test described in item 66711, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP	30.15
66715	A test described in item 66711, if rendered by a receiving APP, where one test in the item has been rendered by the referring APP—one test	12.85
66716	TSH quantitation	25.05
66719	Thyroid function tests (comprising the service described in item 66716 and one or more of the following tests—free thyroxine, free T3, for a patient, if at least one of the following conditions is satisfied: (a) the patient has an abnormal level of TSH; (b) the tests are performed: (i) for the purpose of monitoring thyroid disease in the patient; or (ii) to investigate the sick euthyroid syndrome if the patient is an admitted patient; or (iii) to investigate dementia or psychiatric illness of the patient; or (iv) to investigate amenorrhoea or infertility of the patient; (c) the medical practitioner who requested the tests suspects the patient has a pituitary dysfunction; (d) the patient is on drugs that interfere with thyroid hormone metabolism or function	34.80
66722	TSH quantitation described in item 66716 and one test described in item 66695	37.90
66723	A test described in item 66722, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP—one test	37.90
66724	A test described in item 66722, if rendered by a receiving APP, where one or more tests in the item have been rendered by the referring APP—one test	13.15
66725	TSH quantitation described in item 66716 and 2 tests described in item 66695	51.05
66728	TSH quantitation described in item 66716 and 3 tests described in item 66695	64.20
66731	TSH quantitation described in item 66716 and 4 tests described in item 66695	77.40
66734	TSH quantitation described in item 66716 and 5 tests described in item 66695	90.55
66743	Quantitation of alpha‑fetoprotein in serum or other body fluids during pregnancy except if requested as part of item 66750 or 66751	20.10
66749	Amniotic fluid, spectrophotometric examination of, and quantitation of: (a) lecithin/sphingomyelin ratio; or (b) palmitic acid, phosphatidylglycerol or lamellar body phospholipid; or (c) bilirubin, including correction for haemoglobin; one or more tests	32.95
66750	Quantitation, in pregnancy, of any 2 of the following to detect foetal abnormality: (a) total human chorionic gonadotrophin (total HCG); (b) free alpha human chorionic gonadotrophin (free alpha HCG); (c) free beta human chorionic gonadotrophin (free beta HCG); (d) pregnancy associated plasma protein A (PAPP‑A); (e) unconjugated oestriol (uE3); (f) alpha‑fetoprotein (AFP); including (if performed) a service described in item 73527 or 73529	39.75
66751	Quantitation, in pregnancy, of any 3 or more tests described in item 66750	55.25
66752	Quantitation of acetoacetate, beta‑hydroxybutyrate, citrate, oxalate, total free fatty acids, cysteine, homocysteine, cystine, lactate, pyruvate or other amino acids and hydroxyproline (except if performed as part of item 66773 or 66776)—one test	24.70
66755	Two or more tests described in item 66752	38.85
66756	Quantitation of 10 or more amino acids for the diagnosis of inborn errors of metabolism—up to 4 tests in a 12 month period on specimens of plasma, CSF and urine	98.30
66757	Quantitation of 10 or more amino acids for monitoring of previously diagnosed inborn errors of metabolism in one tissue type	98.30
66758	Quantitation of angiotensin converting enzyme, or cholinesterase—one or more tests	24.70
66761	Test for reducing substances in faeces by any method (except reagent strip or dipstick)	13.15
66764	Examination for faecal occult blood (including tests for haemoglobin and its derivatives in the faeces except by reagent strip or dip stick methods) with a maximum of 3 examinations on specimens collected on separate days in a 28 day period	8.90
66767	Two examinations described in item 66764 performed on separately collected and identified specimens	17.85
66770	Three examinations described in item 66764 performed on separately collected and identified specimens	26.70
66773	Quantitation of products of collagen breakdown or formation for the monitoring of patients with proven low bone mineral density and, if performed, a service described in item 66752—one or more tests	24.65
66776	Quantitation of products of collagen breakdown or formation for the monitoring of patients with metabolic bone disease or Paget’s disease of bone and, if performed, a service described in item 66752—one or more tests	24.65
66779	Adrenaline, noradrenaline, dopamine, histamine, hydroxyindoleacetic acid (5HIAA), hydroxymethoxymandelic acid (HMMA), homovanillic acid (HVA), metanephrines, methoxyhydroxyphenylethylene glycol (MHPG), phenylacetic acid (PAA) or serotonin—quantitation—one or more tests	39.95
66780	A test described in item 66779 if rendered by a receiving APP—one or more tests	39.95
66782	Porphyrins or porphyrins precursors—detection in plasma, red cells, urine or faeces—one or more tests	13.15
66783	A test described in item 66782 if rendered by a receiving APP—one or more tests	13.15
66785	Porphyrins or porphyrins precursors—quantitation in plasma, red cells, urine or faeces—one test	39.95
66788	Porphyrins or porphyrins precursors—quantitation in plasma, red cells, urine or faeces—2 or more tests	65.85
66789	A test described in item 66785 if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP—one test	39.95
66790	A test described in item 66785, if rendered by a receiving APP, where one or more tests in the item have been rendered by the referring APP—one test	25.90
66791	Porphyrin biosynthetic enzymes—measurement of activity in blood cells or other tissues—one or more tests	74.45
66792	A test described in item 66791 if rendered by a receiving APP—one or more tests	74.45
66800	Quantitation in blood, urine or other body fluid by any method (except reagent tablet or reagent strip) of any of the following used therapeutically by the patient from whom the specimen was taken: amikacin, carbamazepine, digoxin, disopyramide, ethanol, ethosuximide, gentamicin, lignocaine, lithium, netilmicin, paracetamol, phenobarbitone, phenytoin, primidone, procainamide, quinidine, salicylate, theophylline, tobramycin, valproate or vancomycin—one test	18.15
66803	Two tests described in item 66800	30.50
66804	A test described in item 66800 if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP—one test	18.15
66805	A test described in item 66800, if rendered by a receiving APP, where one or more tests in the item have been rendered by the referring APP—one test	12.35
66806	Three tests described in item 66800	41.85
66812	Quantitation, not elsewhere described in this table by any method or methods, in blood, urine or other body fluid, of a drug being used therapeutically by the patient from whom the specimen was taken—one test	34.80
66815	Two tests described in item 66812	59.55
66816	A test described in item 66812 if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP—one test	34.80
66817	A test described in item 66812, if rendered by a receiving APP, where one or more tests in the item have been rendered by the referring APP—one test	24.75
66819	Quantitation of copper, manganese, selenium or zinc (except if item 66667 applies), in blood, urine or other body fluid—one test	30.60
66820	A test described in item 66819 if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP—one test	30.60
66821	A test described in item 66819, if rendered by a receiving APP, where one or more tests in the item have been rendered by the referring APP—one test	21.80
66822	Quantitation of copper, manganese, selenium or zinc (except if item 66667 applies), in blood, urine or other body fluid—2 or more tests	52.45
66825	Quantitation of aluminium (except if item 66671 applies), arsenic, beryllium, cadmium, chromium, gold, mercury, nickel or strontium, in blood, urine or other body fluid or tissue—one test	30.60
66826	A test described in item 66825 if rendered by a receiving APP where no tests have been rendered by the referring APP—one test	30.60
66827	A test described in item 66825, if rendered by a receiving APP, where one or more tests in the item have been rendered by the referring APP—one test	21.80
66828	Quantitation of aluminium (except if item 66671 applies), arsenic, beryllium, cadmium, chromium, gold, mercury, nickel or strontium, in blood, urine or other body fluid or tissue—2 or more tests	52.45
66830	Quantitation of BNP or NT‑proBNP for the diagnosis of heart failure in patients presenting with dyspnoea in a hospital emergency department	58.50
66831	Quantitation of copper or iron in liver tissue biopsy	30.95
66832	A test described in item 66831 if rendered by a receiving APP	30.95
66833	25‑hydroxyvitamin D, quantification in serum, for the investigation of a patient who: (a) has signs or symptoms of osteoporosis or osteomalacia; or (b) has increased alkaline phosphatase and otherwise normal liver function tests; or (c) has hyperparathyroidism, hypo‑ or hypercalcaemia, or hypophosphataemia; or (d) is suffering from malabsorption (for example, because the patient has cystic fibrosis, short bowel syndrome, inflammatory bowel disease or untreated coeliac disease, or has had bariatric surgery); or (e) has deeply pigmented skin, or chronic and severe lack of sun exposure for cultural, medical, occupational or residential reasons; or (f) is taking medication known to decrease 25OH‑D levels (for example, anticonvulsants); or (g) has chronic renal failure or is a renal transplant recipient; or (h) is less than 16 years of age and has signs or symptoms of rickets; or (i) is an infant whose mother has established vitamin D deficiency; or (j) is an exclusively breastfed baby and has at least one other risk factor mentioned in a paragraph in this item; or (k) has a sibling who is less than 16 years of age and has vitamin D deficiency	30.05
66834	A test described in item 66833 if rendered by a receiving APP	30.05
66835	1, 25‑dihydroxyvitamin D—quantification in serum, if the request for the test is made by, or on advice of, the specialist or consultant physician managing the treatment of the patient	39.05
66836	1, 25‑dihydroxyvitamin D—quantification in serum, if: (a) a patient has hypercalcaemia; and (b) the request for the test is made by a general practitioner managing the treatment of the patient	39.05
66837	A test described in item 66835 or 66836 if rendered by a receiving APP	39.05
66838	Serum vitamin B12 test	23.60
66839	Quantification of vitamin B12 markers such as holoTranscobalamin or methylmalonic acid, where initial serum vitamin B12 result is low or equivocal	42.95
66840	Serum folate test and, if required, red cell folate test for a patient at risk of folate deficiency, including patients with malabsorption conditions, macrocytic anaemia or coeliac disease	23.60
66841	Quantitation of HbA1c (glycated haemoglobin) performed for the diagnosis of diabetes in asymptomatic patients at high risk	16.80
66900	Carbon‑labelled urea breath test using oral C‑13 or C‑14 urea, including the measurement of exhaled 13CO2 or 14CO2, (except if item 12533 of the general medical services table applies) for: (a) the confirmation of Helicobactor pylori colonisation; or (b) the monitoring of the success of eradication of Helicobactor pylori	77.65

Division 2.3—Group P3: microbiology

2.3.1 Meaning of serial examinations or cultures

For an item in Group P3 (Microbiology):

serial examinations or cultures means:

(a) a series of examinations or cultures requested on one occasion whether or not:

(i) the materials are received on different days by the approved pathology practitioner; or

(ii) the examinations or cultures were requested on one or more request forms by the treating practitioner; and

(b) if:

(i) tests are carried out in relation to a patient episode; and

(ii) specimen material from the patient episode is stored; and

(iii) in response to a request made within 14 days of the patient episode, further tests are carried out on the stored material;

the later tests and the earlier tests are taken to be part of one patient episode.

2.3.2 Antigen detection

If a pathology service described in item 69316, 69317, 69319, 69494, 69495, 69496, 69497 or 69498 is rendered as a pathologist‑determinable service, the amount mentioned in the item is not payable for the service unless the recognised pathologist who renders the service records, in writing, the reasons for rendering the service.

2.3.3 Investigation for hepatitis serology

The fee applying in a single patient episode that includes any of items 69475, 69478 and 69481 is the fee specified for only one of those items.

2.3.4 Limitation on certain items

(1) For any particular patient, item 69336 is applicable not more than once in each period of 7 days.

(2) For any particular patient, the following items are applicable not more than once in a 12 month period:

(a) item 69482;

(b) item 69491 or 69492;

(3) For any particular patient, item 69418 or 69419 is applicable not more than twice in a 24 month period.

(4) For any particular patient, item 69380, 69488 or 69489 is applicable not more than twice in a 12 month period.

(5) For any particular patient, each of items 69445, 69451 and 69483 is applicable not more than 4 times in a 12 month period.

2.3.5 Hepatitis C viral RNA testing

For items 69499 and 69500:

Hepatitis C sero‑positive, for a patient, means 2 different assays of Hepatitis C antibodies are positive.

serological status is uncertain, for a patient, means any result where 2 different assays of Hepatitis C antibodies are inconclusive.

Group P3—Microbiology
Item	Pathology service	Fee ($)
69300	Microscopy of wet film material other than blood, from one or more sites, obtained directly from a patient (not cultures) including (if performed): (a) differential cell count; or (b) examination for dermatophytes; or (c) dark ground illumination; or (d) stained preparation or preparations using any relevant stain or stains; one or more tests	12.50
69303	Culture and (if performed) microscopy to detect pathogenic micro‑organisms from nasal swabs, throat swabs, eye swabs and ear swabs (except swabs taken for epidemiological surveillance), including (if performed): (a) pathogen identification and antibiotic susceptibility testing; or (b) a service described in item 69300; specimens from one or more sites	22.00
69306	Microscopy and culture to detect pathogenic micro‑organisms from skin or other superficial sites, including (if performed): (a) pathogen identification and antibiotic susceptibility testing; or (b) a service described in items 69300, 69303, 69312 and 69318; one or more tests on one or more specimens	33.75
69309	Microscopy and culture to detect dermatophytes and other fungi causing cutaneous disease, from skin scrapings, skin biopsies, hair and nails (excluding swab specimens) and including (if performed): (a) the detection of antigens not elsewhere specified in this table; or (b) a service described in items 69300, 69303, 69306, 69312 and 69318; one or more tests on one or more specimens	48.15
69312	Microscopy and culture to detect pathogenic micro‑organisms from urethra, vagina, cervix or rectum (except for faecal pathogens), including (if performed): (a) pathogen identification and antibiotic susceptibility testing; or (b) a service described in items 69300, 69303, 69306 and 69318; one or more tests on one or more specimens	33.75
69316	Detection of Chlamydia trachomatis by any method—one test	28.65
69317	This item applies if: (a) one test described in item 69316 is performed; and (b) one test described in item 69494 is performed	35.85
69318	Microscopy and culture to detect pathogenic micro‑organisms from specimens of sputum (except when part of items 69324, 69327 and 69330), including (if performed): (a) pathogen identification and antibiotic susceptibility testing; or (b) a service described in items 69300, 69303, 69306 and 69312; one or more tests on one or more specimens	33.75
69319	This item applies if: (a) one test described in item 69316 is performed; and (b) 2 tests described in item 69494 are performed	42.95
69321	Microscopy and culture of post‑operative wounds, aspirates of body cavities, synovial fluid, CSF or operative or biopsy specimens, for the presence of pathogenic micro‑organisms involving aerobic and anaerobic cultures and the use of different culture media, and including (if performed): (a) pathogen identification and antibiotic susceptibility testing; or (b) a service described in item 69300, 69303, 69306, 69312 or 69318; specimens from one or more sites	48.15
69324	Microscopy (with appropriate stains) and culture for mycobacteria—one specimen of sputum, urine or other body fluid or one operative or biopsy specimen, including (if performed): (a) microscopy and culture of other bacterial pathogens isolated as a result of this procedure; or (b) pathogen identification and antibiotic susceptibility testing; including a service mentioned in item 69300	43.00
69325	A service described in item 69324 if the microscopy and culture is performed by a receiving APP	43.00
69327	Microscopy (with appropriate stains) and culture for mycobacteria—2 specimens of sputum, urine or other body fluids or operative or biopsy specimens, including (if performed): (a) microscopy and culture of other bacterial pathogens isolated as a result of this procedure; or (b) pathogen identification and antibiotic susceptibility testing; including a service described in item 69300	85.00
69328	A service described in item 69327 if the microscopy and culture is performed by a receiving APP	85.00
69330	Microscopy (with appropriate stains) and culture for mycobacteria—3 specimens of sputum, urine or other body fluids or operative or biopsy specimens, including (if performed): (a) microscopy and culture of other bacterial pathogens isolated as a result of this procedure; or (b) pathogen identification and antibiotic susceptibility testing; including a service described in item 69300	128.00
69331	A service described in item 69330 if the microscopy and culture is performed by a receiving APP	128.00
69333	Urine examination (including serial examination) by any means other than simple culture by dip slide, including: (a) cell count; and (b) culture; and (c) colony count; and (d) (if performed) stained preparations; and (e) (if performed) identification of cultured pathogens; and (f) (if performed) antibiotic susceptibility testing; and (g) (if performed) examination for pH, specific gravity, blood, protein, urobilinogen, sugar, acetone or bile salts	20.55
69336	Microscopy of faeces for ova, cysts and parasites, that includes the use of: (a) a concentration technique; and (b) fixed stains or antigen detection for cryptosporidia and giardia; and includes a service mentioned in item 69300 (if performed)	33.45
69339	Microscopy of faeces for ova, cysts and parasites using concentration techniques examined after examination described in item 69336 performed on a separately collected and identified specimen collected within 7 days of the examination described in item 69336—not more than one examination in a 7 day period	19.10
69345	Culture and (if performed) microscopy without concentration techniques of faeces for faecal pathogens, using at least 2 selective or enrichment media and culture in at least 2 different atmospheres including (if performed): (a) pathogen identification and antibiotic susceptibility testing; and (b) the detection of clostridial toxins; and (c) a service described in item 69300; not more than one examination in a 7 day period	52.90
69354	Blood culture for pathogenic micro‑organisms (other than viruses), including sub‑cultures and (if performed): (a) identification of any cultured pathogen; and (b) necessary antibiotic susceptibility testing; to a maximum of 3 sets of cultures—one set of cultures	30.75
69357	Two sets of cultures described in item 69354	61.45
69360	Three sets of cultures described in item 69354	92.20
69363	Detection of Clostridium difficile or Clostridium difficile toxin (except if a service described in item 69345 has been performed)—one or more tests	28.65
69378	Quantitation of HIV viral RNA load in plasma or serum in the monitoring of a HIV sero‑positive patient not on antiretroviral therapy—one or more tests	180.25
69379	A test described in item 69378 if the quantitation is performed by a receiving APP—one or more tests on one or more specimens	180.25
69380	Genotypic testing for HIV antiretroviral resistance in a patient with confirmed HIV infection if the patient’s viral load is greater than 1 000 copies per ml at any of the following times: (a) at presentation; (b) before antiretroviral therapy; (c) when treatment with combination antiretroviral agents fails; maximum of 2 tests in a 12 month period	770.30
69381	Quantitation of HIV viral RNA load in plasma or serum in the monitoring of a HIV sero‑positive patient on antiretroviral therapy—one or more tests on one or more specimens	180.25
69382	Quantitation of HIV viral RNA load in cerebrospinal fluid in a HIV sero‑positive patient—one or more tests on one or more specimens	180.25
69383	A test described in item 69381 if the quantitation is performed by a receiving APP—one or more tests on one or more specimens	180.25
69384	Quantitation of one antibody to microbial antigens not elsewhere described in this table—one test	15.65
69387	Two tests described in item 69384	29.00
69390	Three tests described in item 69384	42.35
69393	Four tests described in item 69384	55.70
69396	Five or more tests described in item 69384	69.10
69400	A test described in item 69384 if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP—one test	15.65
69401	A test described in item 69384 if a referring APP has performed a test or tests described in item 69384—each test to a maximum of 4 tests	13.35
69405	Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including: (a) the determination of one of the following: rubella immune status, specific syphilis serology, carriage of Hepatitis B, Hepatitis C antibody, HIV antibody; and (b) (if performed) a service described in one or more of items 69384, 69475, 69478 and 69481	15.65
69408	Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including: (a) the determination of 2 of the following: rubella immune status, specific syphilis serology, carriage of Hepatitis B, Hepatitis C antibody, HIV antibody; and (b) (if performed) a service described in one or more of items 69384, 69475, 69478 and 69481	29.00
69411	Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including: (a) the determination of 3 of the following: rubella immune status, specific syphilis serology, carriage of Hepatitis B, Hepatitis C antibody, HIV antibody; and (b) (if performed) a service described in one or more of items 69384, 69475, 69478 and 69481	42.35
69413	Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including: (a) the determination of 4 of the following: rubella immune status, specific syphilis serology, carriage of Hepatitis B, Hepatitis C antibody, HIV antibody; and (b) (if performed) a service described in one or more of items 69384, 69475, 69478 and 69481	55.70
69415	Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including: (a) the determination of all of the following: rubella immune status, specific syphilis serology, carriage of hepatitis B, hepatitis C antibody, HIV antibody; and (b) (if performed) a service described in one or more of items 69384, 69475, 69478 and 69481	69.10
69418	A test for high risk human papillomaviruses (HPV) in a patient who: (a) within the 2 year period before the test, has received excisional or ablative treatment for high grade squamous intraepithelial lesions (HSIL) of the cervix; or (b) within the 2 year period before the test, has had a positive HPV test after excisional or ablative treatment for HSIL of the cervix; or (c) is undergoing annual cytological review following treatment for HSIL of the cervix; one test	63.55
69419	A test described in item 69418 if the test is performed by a receiving APP—one test	63.55
69445	Detection of hepatitis C viral RNA in a patient undertaking antiviral therapy for chronic HCV hepatitis (including a service described in item 69499)—one test	92.20
69451	A test described in item 69445 if the test is performed by a receiving APP—one test	92.20
69471	Test of cell‑mediated immunity in blood for the detection of latent tuberculosis in an immunosuppressed or immunocompromised patient—one test	34.90
69472	Detection of antibodies to Epstein Barr Virus using specific serology—one test	15.65
69474	Detection of antibodies to Epstein Barr Virus using specific serology—2 or more tests	28.65
69475	Detection of hepatitis antigens or antibodies to determine immune status or viral carriage following exposure or vaccination to Hepatitis A, Hepatitis B, Hepatitis C or Hepatitis D—one test	15.65
69478	Two tests described in item 69475	29.25
69481	Investigation of infectious causes of acute or chronic hepatitis—3 tests described in item 69475	40.55
69482	Quantitation of hepatitis B viral DNA in patients who are hepatitis B surface antigen positive and have chronic hepatitis B but are not receiving antiviral therapy—one test	152.10
69483	Quantitation of hepatitis B viral DNA in patients who: (a) are hepatitis B surface antigen positive; and (b) have chronic hepatitis B; and (c) are receiving antiviral therapy; one test	152.10
69484	Supplementary test for hepatitis B surface antigen or hepatitis C antibody using a different assay on a specimen that yielded a reactive result on initial testing	17.10
69488	Quantitation of HCV RNA load in plasma or serum in: (a) the pre‑treatment evaluation, of a patient with chronic HCV hepatitis, for antiviral therapy; or (b) the assessment of efficacy of antiviral therapy for such a patient; if the test is requested by, or on the advice of, the specialist or consultant physician who manages the treatment of the patient (including a service described in item 69445 or 69499)	180.25
69489	A test described in item 69488 if the test is performed by a receiving APP	180.25
69491	Nucleic acid amplification and determination of hepatitis C virus (HCV) genotype if: (a) the patient is HCV RNA positive and is being evaluated for antiviral therapy of chronic HCV hepatitis; and (b) the request for the test is made by, or on the advice of, the specialist or consultant physician managing the treatment of the patient	204.80
69492	A service described in item 69491 if the test is performed by a receiving APP	204.80
69494	Detection of a virus, microbial antigen or microbial nucleic acid (not elsewhere described in this table)—one test	28.65
69495	Two tests described in item 69494	35.85
69496	Three or more tests described in item 69494	43.05
69497	This item applies to a test described in item 69494 if: (a) a referring APP has not performed the test described in item 69494; and (b) a receiving APP performs the test described in item 69494; one test	28.65
69498	This item applies to a test described in item 69494 if: (a) a referring APP has performed the test or tests described in item 69494; and (b) a receiving APP has performed the test or tests described in item 69494; one test	7.20
69499	Detection of hepatitis C viral RNA if at least one of the following criteria is satisfied: (a) the patient is hepatitis C sero‑positive; (b) the patient’s serological status is uncertain after testing; (c) the test is performed for the purpose of: (i) determining the hepatitis C status of an immunosuppressed or immunocompromised patient; or (ii) the detection of acute hepatitis C prior to seroconversion where considered necessary for the clinical management of the patient	92.20
69500	A test described in item 69499 if the test is performed by a receiving APP	92.20

Division 2.4—Group P4: immunology

2.4.1 Limitation on certain items

(1) For any particular patient, items 71075, 71127, 71135 and 71137 are applicable not more than twice in a 12 month period.

(2) For any particular patient, item 71079 is applicable not more than 4 times in a 12 month period.

(3) For any particular patient, item 71077 is applicable not more than 6 times in a 12 month period.

2.4.2 Tests in Group P4 relating to antibodies

For items 71119, 71121, 71123 and 71125, if:

(a) tests are carried out in relation to a patient episode; and

(b) specimen material from the patient episode is stored; and

(c) in response to a request made within 14 days of the patient episode, further tests are carried out on the stored material;

the later tests and the earlier tests are taken to be part of one patient episode.

2.4.3 HLA‑B27 typing

If a pathology service mentioned in item 71148 is rendered as a pathologist‑determinable service, the amount mentioned in the item is not payable for a pathology service mentioned in the item unless the recognised pathologist who renders the service records, in writing, the reasons for rendering the service and the result of the pathology service mentioned in item 71147.

2.4.4 Antineutrophil cytoplasmic antibody tests

For subsection 16A(3) of the Act, a request for an antineutrophil cytoplasmic antibody immunofluorescence test is taken to include a request for an antineutrophil proteinase 3 antibody test and an antimyeloperoxidase antibody test if:

(a) the immunofluorescence test performed as a result of the request is abnormal; or

(b) a previous immunofluorescence test was abnormal; or

Group P4—Immunology
Item	Pathology service	Fee ($)
71057	Electrophoresis, quantitative and qualitative, of serum, urine or other body fluid, collected in a 28 day period, to demonstrate: (a) protein classes; or (b) presence and amount of paraprotein; including the preliminary quantitation of total protein, albumin and globulin—one specimen type	32.90
71058	Examination as described in item 71057—2 or more specimen types	50.50
71059	Immunofixation, immunoelectrophoresis or isoelectric focusing of: (a) urine for detection of Bence Jones proteins; or (b) serum, plasma, or other body fluid; and characterisation of a paraprotein or cryoglobulin—examination of one specimen type (e.g. serum, urine or CSF)	35.65
71060	Examination as described in item 71059 of 2 or more specimen types	44.05
71062	Electrophoresis and immunofixation or immunoelectrophoresis or isoelectric focusing of CSF for the detection of oligoclonal bands and including if required electrophoresis of the patient’s serum for comparison purposes—one or more tests	44.05
71064	Detection and quantitation of cryoglobulins or cryofibrinogen—one or more tests	20.75
71066	Quantitation of total immunoglobulin A (by any method) in serum, urine, or other body fluid—one test	14.55
71068	Quantitation of total immunoglobulin G (by any method) in serum, urine, or other body fluid—one test	14.55
71069	Two tests described in item 71066, 71068, 71072 or 71074	22.75
71071	Three or more tests described in item 71066, 71068, 71072 or 71074	30.95
71072	Quantitation of total immunoglobulin M (by any method) in serum, urine, or other body fluid—one test	14.55
71073	Quantitation of all 4 immunoglobulin G subclasses	106.15
71074	Quantitation of total immunoglobulin D (by any method) in serum, urine, or other body fluid—one test	14.55
71075	Quantitation of immunoglobulin E (total)—one test	23.00
71076	A test described in item 71073 if the test is performed by a receiving APP—one test	106.15
71077	Quantitation of immunoglobulin E (total) in the follow up of a patient with proven immunoglobulin‑E‑secreting myeloma, proven congenital immunodeficiency or proven allergic bronchopulmonary aspergillosis—one test	27.05
71079	Detection of specific immunoglobulin E antibodies to single or multiple potential allergens	26.80
71081	Quantitation of total haemolytic complement	40.55
71083	Quantitation of complement components C3 and C4 or properdin factor B—one test	20.15
71085	Two tests described in item 71083	28.95
71087	Three or more tests described in item 71083	37.70
71089	Quantitation of complement components or breakdown products of complement proteins not elsewhere described in an item in this table—one test	29.15
71090	This item applies to a test described in item 71089 if: (a) a referring APP has not performed the test described in item 71089; and (b) a receiving APP performs the test described in item 71089; one test	29.15
71091	Two tests described in item 71089	52.85
71092	This item applies to a test described in item 71089 if: (a) a referring APP has performed the test or tests described in item 71089; and (b) a receiving APP performs the test or tests described in item 71089; one test	23.70
71093	Three or more tests described in item 71089	76.45
71095	Quantitation of serum or plasma eosinophil cationic protein, or both, to a maximum of 3 assays in a 12 month period, for monitoring the response to therapy in corticosteroid treated asthma, in a child aged less than 12 years	40.55
71096	A test described in item 71095 if the quantitation is performed by a receiving APP	40.55
71097	Antinuclear antibodies—detection in serum or other body fluids, including quantitation if required	24.45
71099	Double‑stranded DNA antibodies—quantitation by one or more methods other than the Crithidia method	26.50
71101	Antibodies to one or more extractable nuclear antigens—detection in serum or other body fluids	17.40
71103	Characterisation of an antibody detected in a service described in item 71101 (including that service)	52.05
71106	Rheumatoid factor—detection by any technique in serum or other body fluids, including quantitation if required	11.30
71119	Antibodies to tissue antigens not elsewhere specified in this table—detection of one antibody, including quantitation if required	17.35
71121	Detection of 2 antibodies specified in item 71119	20.80
71123	Detection of 3 antibodies specified in item 71119	24.25
71125	Detection of 4 or more antibodies specified in item 71119	27.65
71127	Functional tests for lymphocytes—quantitation, other than by microscopy, of: (a) proliferation induced by one or more mitogens; or (b) proliferation induced by one or more antigens; or (c) estimation of one or more mixed lymphocyte reactions; including a test described in item 65066 or 65070 (if performed)	176.35
71129	Two tests described in item 71127	217.85
71131	Three or more tests described in item 71127	259.35
71133	Investigation of recurrent infection, by qualitative assessment, for the presence of defects in oxidative pathways in neutrophils by the nitroblue tetrazolium (NBT) reduction test	10.40
71134	Investigation of recurrent infection, by quantitative assessment, of oxidative pathways by flow cytometric techniques, including a test described in item 71133 (if performed)	104.05
71135	Quantitation of neutrophil function, comprising at least 2 of the following: (a) chemotaxis; (b) phagocytosis; (c) oxidative metabolism; (d) bactericidal activity; including any test described in item 65066, 65070, 71133 or 71134 (if performed)	207.95
71137	Quantitation of cell‑mediated immunity by multiple antigen delayed type hypersensitivity intradermal skin testing using a minimum of 7 antigens	30.25
71139	Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations, including a total lymphocyte count or total leucocyte count by any method, on one or more specimens of blood, CSF or serous fluid	104.05
71141	Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations on one or more disaggregated tissue specimens	197.35
71143	Characterisation of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations for the diagnosis (but not monitoring) of an immunological or haematological malignancy, including a service described in one or both of items 71139 and 71141 (if performed), on a specimen of blood, CSF, serous fluid or disaggregated tissue	260.00
71145	Characterisation of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations for the diagnosis (but not monitoring) of an immunological or haematological malignancy, including a service described in one or more of items 71139, 71141 and 71143 (if performed) on 2 or more specimens of disaggregated tissues or one specimen of disaggregated tissue and one or more specimens of blood, CSF or serous fluid	424.50
71146	Enumeration of CD34+ cells, only for the purposes of autologous or directed allogeneic haemopoietic stem cell transplantation, including a total white cell count on the pheresis collection	104.05
71147	HLA‑B27 typing	40.55
71148	A test described in item 71147 if a receiving APP performs the test	40.55
71149	Complete tissue typing for 4 HLA‑A and HLA‑B Class I antigens (including any separation of leucocytes), including (if performed) a service described in item 71147	108.25
71151	Tissue typing for HLA‑DR, HLA‑DP and HLA‑DQ Class II antigens (including any separation of leucocytes)—phenotyping or genotyping of 2 or more antigens	118.85
71153	Testing, for assessment or diagnosis of systemic inflammatory disease or vasculitis, for the presence of an antibody by one of the following tests: (a) antineutrophil cytoplasmic antibody (ANCA) immunofluorescence test; (b) antineutrophil proteinase 3 antibody (PR3 ANCA) test; (c) antimyeloperoxidase antibody (MPO ANCA) test; (d) antiglomerular basement membrane antibody (GBM ANCA) test	34.55
71154	This item applies to a test described in item 71153 if: (a) a referring APP has performed a test or tests described in item 71153; and (b) a receiving APP performs the test described in item 71153; one test	34.55
71155	Testing for the presence of 2 antibodies by tests mentioned in item 71153	47.45
71156	This item applies to a test described in item 71153 (other than a test described in item 71154) if: (a) a referring APP has performed the test or tests described in item 71153; and (b) a receiving APP performs the test or tests described in item 71153; one test	12.85
71157	Testing for the presence of 3 antibodies by tests mentioned in item 71153	60.30
71159	Testing for the presence of 4 antibodies by tests mentioned in item 71153	73.15
71163	Detection of one of the following antibodies (of one or more class or isotype) in the assessment or diagnosis of coeliac disease or other gluten hypersensitivity syndromes, including a service described in item 71066 (if performed): (a) antibodies to gliadin; (b) antibodies to endomysium; (c) antibodies to tissue transglutaminase; one test	24.75
71164	Two or more tests mentioned in item 71163, including a service described in item 71066 (if performed)	39.90
71165	Antibodies to tissue antigens (acetylcholine receptor, adrenal cortex, heart, histone, insulin, insulin receptor, intrinsic factor, islet cell, lymphocyte, neuron, ovary, parathyroid, platelet, salivary gland, skeletal muscle, skin basement membrane and intercellular substance, thyroglobulin, thyroid microsome or thyroid stimulating hormone receptor)—detection of one antibody, including quantitation if required	34.55
71166	Detection of 2 antibodies described in item 71165	47.45
71167	Detection of 3 antibodies described in item 71165	60.30
71168	Detection of 4 or more antibodies described in item 71165	73.15
71169	This item applies to a service described in item 71165 if: (a) a referring APP has not performed the service described in item 71165; and (b) a receiving APP performs the service described in item 71165	34.55
71170	This item applies to a service described in item 71165 if: (a) a referring APP has performed the test or tests described in item 71165; and (b) a receiving APP performs the test or tests described in item 71165; one test	12.85
71180	Antibody to cardiolipin or beta‑2 glycoprotein I—detection, including quantitation if required; one antibody specificity (IgG or IgM)	34.55
71183	Detection of 2 antibodies described in item 71180	47.45
71186	Detection of 3 or more antibodies described in item 71180	60.30
71189	Detection of specific IgG antibodies to one or more respiratory disease allergens not elsewhere specified	15.50
71192	Two items described in item 71189	28.35
71195	Three or more items described in item 71189	40.05
71198	Estimation of serum tryptase for the evaluation of unexplained acute hypotension or suspected anaphylactic event, assessment of risk in stinging insect anaphylaxis, exclusion of mastocytosis, monitoring of known mastocytosis	40.55
71200	Detection and quantitation, if present, of free kappa and lambda light chains in serum for the diagnosis or monitoring of amyloidosis, myeloma or plasma cell dyscrasias	59.60
71203	Determination of HLAB5701 status by flow cytometry or cytotoxity assay prior to the initiation of Abacavir therapy including item 73323 (if performed)	40.55

Division 2.5—Group P5: tissue pathology

2.5.1 Tests on biopsy material

(1) For items in Group P5 (Tissue pathology):

biopsy material means all tissue received by an approved pathology practitioner:

(a) from a medical procedure, or group of medical procedures, performed on a patient at the same time; or

(b) after being expelled spontaneously from a patient.

cytology means microscopic examination of one or more stained preparations of cells separated naturally or artificially from their normal environment by methods recognised as adequate to demonstrate their structure to a degree sufficient to enable an opinion to be formed about whether they are likely to be normal, abnormal but benign, or abnormal and malignant but, in accordance with customary laboratory practice, does not include examination of a blood film or a bone marrow aspirate.

separately identified specimen means an individual specimen collected, identified so that it is clearly distinguished from any other specimen, and sent for testing by or on behalf of the treating practitioner responsible for the procedure in which the specimen was taken.

(2) For Group P5, services in Group P6 (Cytology) include any services described in Group P5 on the material submitted for a test in Group P6.

(3) For subclause (2), any sample submitted for cytology from which a cell block is prepared does not qualify for a Group P5 item.

(4) If more than one of the services mentioned in items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72827, 72828, 72830, 72836 and 72838 are performed in a single patient episode, only the fee for the item performed having the highest specified fee is applicable to the services.

(5) If more than one histopathological examination is performed on separate specimens, of different complexity levels, from a single patient episode, only the fee for the examination having the highest specified fee is applicable to the examinations.

(6) In items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72827, 72828, 72830, 72836 and 72838 a reference to a complexity level is a reference to the level given to a specimen type mentioned in Part 4 of this table.

(7) If:

(a) more than one of the services mentioned in items 72846, 72847, 72848, 72849 and 72850; or

(b) more than one of the services mentioned in items 73059, 73060, 73061, 73064 and 73065;

are performed in a single patient episode, only the fee for the item performed having the higher or highest specified fee applies to the services.

Group P5—Tissue pathology
Item	Pathology service	Fee ($)
72813	Examination of complexity level 2 biopsy material with one or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions—one or more separately identified specimens	71.50
72816	Examination of complexity level 3 biopsy material with one or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions—one separately identified specimen	86.35
72817	Examination of complexity level 3 biopsy material with one or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions—2 to 4 separately identified specimens	96.80
72818	Examination of complexity level 3 biopsy material with one or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions—5 or more separately identified specimens	107.05
72823	Examination of complexity level 4 biopsy material with one or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions—one separately identified specimen	97.15
72824	Examination of complexity level 4 biopsy material with one or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions—2 to 4 separately identified specimens	141.35
72825	Examination of complexity level 4 biopsy material with one or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions—5 to 7 separately identified specimens	180.25
72826	Examination of complexity level 4 biopsy material with one or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions—8 to 11 separately identified specimens	194.60
72827	Examination of complexity level 4 biopsy material with one or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions—12 to 17 separately identified specimens	208.95
72828	Examination of complexity level 4 biopsy material with one or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions—18 or more separately identified specimens	223.30
72830	Examination of complexity level 5 biopsy material with one or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions—one or more separately identified specimens	274.15
72836	Examination of complexity level 6 biopsy material with one or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions—one or more separately identified specimens	417.20
72838	Examination of complexity level 7 biopsy material with multiple tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy, and professional opinion or opinions—one or more separately identified specimens	466.85
72844	Enzyme histochemistry of skeletal muscle for investigation of primary degenerative or metabolic muscle diseases or of muscle abnormalities secondary to disease of the central or peripheral nervous system—one or more tests	30.75
72846	Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen—one to 3 antibodies except those mentioned in item 72848	59.60
72847	Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen—4 to 6 antibodies	89.40
72848	Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen—one to 3 of the following antibodies: (a) oestrogen; (b) progesterone; (c) c‑erb‑B2 (HER2)	74.50
72849	Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen—7 to 10 antibodies	104.30
72850	Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen—11 or more antibodies	119.20
72851	Electron microscopic examination of biopsy material—one separately identified specimen	184.35
72852	Electron microscopic examination of biopsy material—2 or more separately identified specimens	245.80
72855	Intraoperative consultation and examination of biopsy material by frozen section or tissue imprint or smear—one separately identified specimen	184.35
72856	Intraoperative consultation and examination of biopsy material by frozen section or tissue imprint or smear—2 to 4 separately identified specimens	245.80
72857	Intraoperative consultation and examination of biopsy material by frozen section or tissue imprint or smear—5 or more separately identified specimens	286.75

Division 2.6—Group P6: cytology

2.6.1 Tests on biopsy material

(1) For Group P6 (Cytology), services in Group P6 include any services described in Group P5 (Tissue pathology) on the material submitted for a test in Group P6.

(2) For subclause (1), any sample submitted for cytology from which a cell block is prepared does not qualify for a Group P5 item.

(3) If:

(a) more than one of the services mentioned in items 72846, 72847, 72848, 72849 and 72850; or

(b) more than one of the services mentioned in items 73059, 73060, 73061, 73064 and 73065;

are performed in a single patient episode, only the fee for the item performed having the higher or highest specified fee applies to the services.

(4) If more than one of the services mentioned in items 73049, 73051, 73062, 73063, 73066 and 73067 are performed in a single patient episode, the fee for the combined services is:

(a) if services mentioned in 2 items are performed—the higher of the 2 fees specified; or

(b) if services mentioned in more than 2 items are performed—the highest of the fees specified.

Group P6—Cytology
Item	Pathology service	Fee ($)
73043	Cytology (including serial examinations) of nipple discharge or smears from skin, lip, mouth, nose or anus for detection of precancerous or cancerous changes—one or more tests	22.85
73045	Cytology (including serial examinations) for malignancy (other than an examination mentioned in item 73053), including any Group P5 service (if performed), one or more tests on: (a) specimens resulting from washings or brushings from sites not specified in item 73043; or (b) a single specimen of sputum or urine; or (c) one or more specimens of other body fluids	48.60
73047	Cytology of a series of 3 sputum or urine specimens for malignant cells	94.70
73049	Cytology of material obtained directly from a patient by fine needle aspiration of solid tissue, or tissues—one identified site	68.15
73051	Cytology of material obtained directly from a patient at one identified site by fine needle aspiration of solid tissue or tissues if a recognised pathologist: (a) performs the aspiration; or (b) attends the aspiration and performs a cytological examination during the attendance	170.35
73053	Cytology of a smear from cervix, where the smear is prepared by direct application of the specimen to a slide, excluding the use of liquid based slide preparation techniques, and the stained smear is microscopically examined by or on behalf of a pathologist—each examination: (a) for the detection of precancerous or cancerous changes in women with no symptoms, signs or recent history suggestive of cervical neoplasia; or (b) if a further specimen is taken due to an unsatisfactory smear taken for the purposes of paragraph (a); or (c) if there is inadequate information provided to use item 73055	19.45
73055	Cytology of a smear from cervix, not associated with item 73053, where the smear is prepared by direct application of the specimen to a slide, excluding the use of liquid based slide preparation techniques, and the stained smear is microscopically examined by or on behalf of a pathologist—each test: (a) for the management of previously detected abnormalities including precancerous or cancerous conditions; or (b) for the investigation of women with symptoms, signs or recent history suggestive of cervical neoplasia	19.45
73057	Cytology of a smear from vagina, not associated with item 73053 or 73055, and not to monitor hormone replacement therapy, where the smear is prepared by direct application of the specimen to a slide, excluding the use of liquid based slide preparation techniques, and the stained smear is microscopically examined by or on behalf of a pathologist—each test	19.45
73059	Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049, 73051, 73062 73063, 73066 and 73067 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen—one to 3 antibodies except those mentioned in item 73061	43.00
73060	Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049, 73051, 73062 73063, 73066 and 73067 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen—4 to 6 antibodies	57.35
73061	Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049, 73051, 73062 73063, 73066 and 73067 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen—one to 3 of the following antibodies: (a) oestrogen; (b) progesterone; (c) c‑erb‑B2 (HER2)	51.20
73062	Cytology of material obtained directly from a patient by fine needle aspiration of solid tissue, or tissues—2 or more separately identified sites	89.00
73063	Cytology of material obtained directly from a patient at one identified site by fine needle aspiration of solid tissue, or tissues, if an employee of an approved pathology authority attends the aspiration for confirmation of sample adequacy	99.35
73064	Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049, 73051, 73062 73063, 73066 and 73067 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen—7 to 10 antibodies	71.70
73065	Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049, 73051, 73062 73063, 73066 and 73067 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen—11 or more antibodies	86.00
73066	Cytology of material obtained directly from a patient at 2 or more separately identified sites by fine needle aspiration of solid tissue, or tissues, if a recognised pathologist: (a) performs the aspiration; or (b) attends the aspiration and performs cytological examination during the attendance	221.45
73067	Cytology of material obtained directly from a patient at 2 or more separately identified sites by fine needle aspiration of solid tissue, or tissues, if an employee of an approved pathology authority attends the aspiration for confirmation of sample adequacy	129.15

Division 2.7—Group P7: genetics

2.7.1 Haemochromatosis testing

For items 73317 and 73318:

elevated serum ferritin, for a patient, means a level of ferritin above the normal reference range for the particular method of assay used to determine the level.

2.7.2 HLA‑B27 typing

If a pathology service mentioned in item 73320 or 73321 is rendered as a pathologist‑determinable service, the amount mentioned in the item is not payable for a pathology service mentioned in the item unless the recognised pathologist who renders the service records, in writing, the reasons for rendering the service and the result of the pathology service mentioned in item 71147.

2.7.3 Limitation on items 73339 and 73340

For any particular patient, each of items 73339 and 73340 is applicable only once.

Group P7—Genetics
Item	Pathology service	Fee ($)
73287	Study of the whole of every chromosome by cytogenetics or other techniques, performed on one or more of any tissue or fluid except blood (including a service mentioned in item 73293, if performed)—one or more tests	394.55
73289	Study of the whole of every chromosome by cytogenetics or other techniques, performed on blood (including a service mentioned in item 73293, if performed)—one or more tests	358.95
73290	Study of the whole of every chromosome by cytogenetics or other techniques, performed on blood or bone marrow, to diagnose or monitor haematological malignancy (including a service mentioned in item 73287 or 73289, if performed)—one or more tests	394.55
73291	Analysis of one or more chromosome regions, performed on blood or fresh tissue, for specific constitutional genetic abnormalities in: (a) diagnostic studies of a person with developmental delay, intellectual disability, autism, or at least 2 congenital abnormalities, in whom a study by cytogenetics or other techniques mentioned in item 73287 or 73289 is normal or has not been performed—one or more tests; or (b) studies of a relative of the person for an abnormality previously identified in the person—one or more tests	230.95
73292	Analysis of chromosomes by genome‑wide microarray, including targeted assessment of specific regions for constitutional genetic abnormalities in diagnostic studies of a person with developmental delay, intellectual disability, autism, or at least 2 congenital abnormalities (including a service mentioned in item 73287, 73289 or 73291, if performed)—one or more tests	589.90
73293	Analysis of one or more regions on all chromosomes, performed on fresh tissue, for specific constitutional genetic abnormalities in diagnostic studies of the products of conception, including exclusion of maternal cell contamination—one or more tests	230.95
73294	Analysis of the PMP22 gene for constitutional genetic abnormalities causing peripheral neuropathy, as: (a) diagnostic studies of a person with peripheral neuropathy—one or more tests; or (b) studies of a relative of the person for an abnormality previously identified in the person—one or more tests	230.95
73300	Detection of mutation of the FMR1 gene if: (a) the patient exhibits intellectual disability, ataxia, neurodegeneration, or premature ovarian failure consistent with an FMR1 mutation; or (b) the patient has a relative with an FMR1 mutation; one or more tests	101.30
73305	Detection of a mutation of the FMR1 gene by Southern Blot analysis, if the results of a service performed in item 73300 are inconclusive	202.65
73308	Characterisation of the genotype of a patient for Factor V Leiden gene mutation, or detection of other relevant mutations in the investigation of proven venous thrombosis or pulmonary embolism—one or more tests	36.45
73309	A test described in item 73308 if the test is performed by a receiving APP—one or more tests	36.45
73311	Characterisation of the genotype of a person who is a first degree relative of a person who has been proven to have one or more abnormal genotypes under item 73308—one or more tests	36.45
73312	A test described in item 73311 if the test is performed by a receiving APP—one or more tests	36.45
73314	Characterisation of gene rearrangement or the identification of mutations within a known gene rearrangement in the diagnosis and monitoring of patients with laboratory evidence of: (a) acute myeloid leukaemia; or (b) acute promyelocytic leukaemia; or (c) acute lymphoid leukaemia; or (d) chronic myeloid leukaemia	230.95
73315	A service described in item 73314 if the characterisation is performed by a receiving APP—one or more tests	230.95
73317	Detection of the C282Y genetic mutation of the HFE gene and, if performed, detection of other mutations for haemochromatosis where: (a) the patient has an elevated transferrin saturation or elevated serum ferritin on testing of repeated specimens; or (b) the patient has a first degree relative with haemochromatosis; or (c) the patient has a first degree relative with homozygosity for the C282Y genetic mutation, or with compound heterozygosity for recognised genetic mutations for haemochromatosis	36.45
73318	A test described in item 73317 if the detection is performed by a receiving APP—one or more tests	36.45
73320	Detection of HLA‑B27 by nucleic acid amplification including a service described in item 71147 unless the service in this item is rendered as a pathologist‑determinable service	40.55
73321	A test described in item 73320 if the detection is performed by a receiving APP—one or more tests	40.55
73323	Determination of HLAB5701 status by molecular techniques prior to the initiation of Abacavir therapy including item 71203 (if performed)	40.55
73324	A test described in item 73323 if rendered by a receiving APP—one or more tests	40.95
73325	Characterisation of mutations in: (a) the JAK2 gene; or (b) the MPL gene; or (c) both genes; in the diagnostic work‑up, by or on behalf of a specialist or consultant physician, of a patient with clinical and laboratory evidence of: (d) polycythaemia vera; or (e) essential thrombocythaemia; one or more tests	74.50
73326	Characterisation of the gene rearrangement FIP1L1‑PDGFRA in the diagnostic work‑up and management of a patient with laboratory evidence of: (a) mast cell disease; or (b) idiopathic hypereosinophilic syndrome; or (c) chronic eosinophilic leukaemia; one or more tests	230.95
73327	Detection of genetic polymorphisms in the Thiopurine S‑methyltransferase gene for the prevention of dose‑related toxicity during treatment with thiopurine drugs, including (if performed) any service described in item 65075—one or more tests	51.95
73332	An in situ hybridisation (ISH) test of tumour tissue from a patient with breast cancer requested by, or on the advice of, a specialist or consultant physician who manages the treatment of the patient to determine if the requirements relating to human epidermal growth factor receptor 2 (HER2) gene amplification for access to trastuzumab under the Pharmaceutical Benefits Scheme or the Herceptin Program are fulfilled	315.40
73333	Detection of germline mutations of the von Hippel‑Lindau (VHL) gene: (a) in a patient who has a clinical diagnosis of VHL syndrome and: (i) a family history of VHL syndrome and one of the following: (A) haemangioblastoma (retinal or central nervous system); (B) phaeochromocytoma; (C) renal cell carcinoma; or (ii) 2 or more haemangioblastomas; or (iii) one haemangioblastoma and a tumour or a cyst of: (A) the adrenal gland; or (B) the kidney; or (C) the pancreas; or (D) the epididymis; or (E) a broad ligament (other than epididymal and single renal cysts, which are common in the general population); or (b) in a patient presenting with one or more of the following clinical features suggestive of VHL syndrome: (i) haemangiblastomas of the brain, spinal cord, or retina; (ii) phaeochromocytoma; (iii) functional extra‑adrenal paraganglioma	600.00
73334	Detection of germline mutations of the von Hippel‑Lindau (VHL) gene in biological relatives of a patient with a known mutation in the VHL gene	340.00
73335	Detection of somatic mutations of the von Hippel‑Lindau (VHL) gene in a patient with: (a) 2 or more tumours comprising: (i) 2 or more haemangioblastomas, or (ii) one haemangioblastomas and a tumour of: (A) the adrenal gland; or (B) the kidney; or (C) the pancreas; or (D) the epididymis; and (b) no germline mutations of the VHL gene identified by genetic testing	470.00
73336	A test of tumour tissue from a patient with unresectable stage III or stage IV metastatic cutaneous melanoma, requested by, or on behalf of, a specialist or consultant physician, to determine if the requirements relating to BRAF V600 mutation status for access to dabrafenib under the Pharmaceutical Benefits Scheme are fulfilled	230.95
73337	A test of tumour tissue from a patient diagnosed with non‑small cell lung cancer, shown to have non‑squamous histology or histology not otherwise specified, requested by, or on behalf of, a specialist or consultant physician, to determine if the requirements relating to epidermal growth factor receptor (EGFR) gene status for access to erlotinib or gefitinib under the Pharmaceutical Benefits Scheme are fulfilled	397.35
73339	Detection of germline mutations in the RET gene in patients with a suspected clinical diagnosis of multiple endocrine neoplasia type 2 (MEN2) requested by a specialist or consultant physician who manages the treatment of the patient—one test	400.00
73340	Detection of a known mutation in the RET gene in an asymptomatic relative of a patient with a documented pathogenic germline RET mutation requested by a specialist or consultant physician who manages the treatment of the patient—one test	200.00

Division 2.8—Group P8: infertility and pregnancy tests

2.8.1 Limitation on item 73523

For any particular patient, item 73523 is applicable not more than 4 times in a 12 month period.

Group P8—Infertility and pregnancy tests
Item	Pathology service	Fee ($)
73521	Semen examination for presence of spermatozoa or examination of cervical mucus for spermatozoa (Huhner’s test)	9.70
73523	Semen examination (other than post‑vasectomy semen examination), including: (a) measurement of volume, sperm count and motility; and (b) examination of stained preparations; and (c) morphology; and (d) (if performed) differential count and one or more chemical tests	41.75
73525	Sperm antibodies—sperm‑penetrating ability—one or more tests	28.35
73527	Human chorionic gonadotrophin (HCG)—detection in serum or urine by one or more methods for diagnosis of pregnancy—one or more tests	10.00
73529	Human chorionic gonadotrophin (HCG), quantitation in serum by one or more methods (except by latex, membrane, strip or other pregnancy test kit) for diagnosis of threatened abortion, or follow up of abortion or diagnosis of ectopic pregnancy, including any services performed in item 73527—one test	28.65

Division 2.9—Group P9: simple basic pathology tests

Group P9—Simple basic pathology tests
Item	Pathology service	Fee ($)
73801	Semen examination for presence of spermatozoa	6.90
73802	Leucocyte count, erythrocyte sedimentation rate, examination of blood film (including differential leucocyte count), haemoglobin, haematocrit or erythrocyte count—one test	4.55
73803	Two tests described in item 73802	6.35
73804	Three or more tests described in item 73802	8.15
73805	Microscopy of urine, whether stained or not, or catalase test	4.55
73806	Pregnancy test by one or more immunochemical methods	10.15
73807	Microscopy for wet film other than urine, including any relevant stain	6.90
73808	Microscopy of Gram‑stained film, including (if performed) a service described in item 73805 or 73807	8.65
73809	Chemical tests for occult blood in faeces by reagent stick, strip, tablet or similar method	2.35
73810	Microscopy for fungi in skin, hair or nails—one or more sites	6.90
73811	Mantoux test	11.20

Division 2.10—Group P10: patient episode initiation

2.10.1 Items in Group P10 not to apply in certain circumstances

(1) In this Division:

approved collection centre has the meaning given by subsection 23DA(1) of the Act.

institution means a place at which residential accommodation or day care is, or both residential accommodation and day care are, made available to:

(a) disadvantaged children; or

(b) juvenile offenders; or

(d) chronically ill psychiatric patients; or

(e) homeless persons; or

(f) unemployed persons; or

(g) persons suffering from alcoholism; or

(h) persons addicted to drugs; or

(i) physically or mentally handicapped persons;

but does not include:

(j) a hospital; or

(k) a residential care facility; or

(l) accommodation for aged persons that is attached to a residential care facility or situated within a residential care facility complex.

prescribed laboratory means a laboratory operated by:

(a) the Commonwealth; or

(b) an authority of the Commonwealth; or

(d) an authority of a State or internal Territory; or

(e) an Australian tertiary education institution.

residential care facility means a facility in which residential care, within the meaning of section 41‑3 of the Aged Care Act 1997, is provided.

specimen collection centre has the meaning given by subsection 23DA(1) of the Act.

treating practitioner has the same meaning as in paragraph 16A(1)(a) of the Act.

(2) If a service mentioned in an item in Group P10 is rendered by, or on behalf of, an approved pathology practitioner who is a recognised pathologist, the relevant item does not apply to the service if:

(a) the service is rendered upon a request made in the course of an out‑patient service at a recognised hospital; or

(b) the service is rendered to a public patient at a recognised hospital.

(3) An item in Group P10 does not apply to a pathology service to which subsection 16A(7) of the Act applies.

(4) An item in Group P10 does not apply to a pathology service unless at least one item in Groups P1 to P8 also applies to the service.

(5) Subject to subclause (6), if one item in Group P10 applies to a patient episode, no other item in the Group applies to the patient episode.

(6) If, for the same patient episode:

(a) services mentioned in one or more items in Group P5 and one or more of Groups P1, P2, P3, P4, P6, P7 and P8 are rendered by an approved pathology practitioner in the laboratory of another approved pathology authority; or

(b) services mentioned in one or more items in Group P6 and one or more of Groups P1, P2, P3, P4, P5, P7 and P8 are rendered by an approved pathology practitioner in the laboratory of another approved pathology authority;

the fee mentioned in the applicable item in Group P10 applies to both approved pathology practitioners.

(7) If more than one specimen is collected from a person on the same day for the provision of pathology services:

(a) in accordance with more than one request; and

(b) in or by a single approved pathology authority;

the fee mentioned in the applicable item in Group P10 applies once only to the services unless an exemption mentioned in clause 1.2.3, 2.1.1 or 2.2.2 applies or the Minister has made a direction under subsection 4B(3) of the Act.

Group P10—Patient episode initiation
Item	Pathology service	Fee ($)
73920	Initiation of a patient episode by collection of a specimen for one or more services (other than those described in item 73922, 73924 or 73926) if the specimen is collected in an approved collection centre that the approved pathology authority operates in the same premises as it operates a category GX or GY pathology laboratory	2.40
73922	Initiation of a patient episode that consists of a service described in item 73053, 73055 or 73057 (in circumstances other than those described in item 73923)	8.20
73923	Initiation of a patient episode that consists of a service described in item 73053, 73055 or 73057 if: (a) the person is a private patient in a recognised hospital; or (b) the person receives the service from a prescribed laboratory	2.40
73924	Initiation of a patient episode that consists of one or more services described in items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72827, 72828, 72830, 72836 and 72838 (in circumstances other than those described in item 73925) from a person who is an inpatient of a hospital	14.65
73925	Initiation of a patient episode that consists of one or more services described in items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72827, 72828, 72830, 72836 and 72838 if the person is: (a) a private patient of a recognised hospital; or (b) a private patient of a hospital who receives the service or services from a prescribed laboratory	2.40
73926	Initiation of a patient episode that consists of one or more services described in items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72827, 72828, 72830, 72836 and 72838 (in circumstances other than those described in item 73927) from a person who is not a patient of a hospital	8.20
73927	Initiation of a patient episode by a prescribed laboratory that consists of one or more services described in items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72827, 72828, 72830, 72836 and 72838 from a person who is not a patient of a hospital	2.40
73928	Initiation of a patient episode by collection of a specimen for one or more services (in circumstances other than those described in item 73920, 73922, 73923, 73924, 73925, 73926, 73927 or 73929) if the specimen is collected in an approved collection centre	5.95
73929	Initiation of a patient episode by collection of a specimen for one or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926 or 73927) if the specimen is collected in an approved collection centre by: (a) an approved pathology practitioner of a prescribed laboratory; or (b) an employee of an approved pathology authority of a prescribed laboratory	2.40
73930	Initiation of a patient episode by collection of a specimen for one or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926, 73927 or 73931) if the specimen is collected from a person who is an inpatient of a hospital other than a recognised hospital by an approved pathology practitioner or an employee of an approved pathology authority	5.95
73931	Initiation of a patient episode by collection of a specimen for one or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926 or 73927) if the specimen is collected: (a) from a person who is a private patient of a hospital by an approved pathology practitioner of a prescribed laboratory; or (b) from a person who is a private patient of a hospital by an employee of an approved pathology authority that operates a prescribed laboratory; or (c) from a person who is a private patient of a recognised hospital by an approved pathology practitioner of an approved pathology authority; or (d) from a person who is a private patient of a recognised hospital by an employee of an approved pathology authority	2.40
73932	Initiation of a patient episode by collection of a specimen for one or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926, 73927 or 73933) if the specimen is collected from a person in the place where the person resides, and that place is not an institution, by: (a) an approved pathology practitioner of an approved pathology authority; or (b) an employee of an approved pathology authority	10.25
73933	Initiation of a patient episode by collection of a specimen for one or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926 or 73927) if the specimen is collected from a person in the place where the person resides, and that place is not an institution, by: (a) an approved pathology practitioner of a prescribed laboratory; or (b) an employee of an approved pathology authority that operates a prescribed laboratory	2.40
73934	Initiation of a patient episode by collection of a specimen for one or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926, 73927 or 73935) if the specimen is collected from a person in an institution by: (a) an approved pathology practitioner; or (b) an employee of an approved pathology authority	17.60
73935	Initiation of a patient episode by collection of a specimen for one or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926 or 73927) if the specimen is collected from a person in an institution by: (a) an approved pathology practitioner of a prescribed laboratory; or (b) an employee of an approved pathology authority that operates a prescribed laboratory	2.40
73936	Initiation of a patient episode by collection of a specimen for one or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926, 73927 or 73937) if the specimen is collected from the person by the person	5.95
73937	Initiation of a patient episode by collection of a specimen for one or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926 or 73927) if the specimen is collected from the person by the person, and: (a) the service is performed in a prescribed laboratory; or (b) the person is a private patient in a recognised hospital	2.40
73938	Initiation of a patient episode by collection of a specimen for one or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926, 73927 or 73939) if the specimen is collected by, or on behalf of, the treating practitioner	7.95
73939	Initiation of a patient episode by collection of a specimen for one or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926 or 73927) if the specimen is collected by, or on behalf of, the treating practitioner and: (a) the service is performed in a prescribed laboratory; or (b) the person is a private patient in a recognised hospital	2.40

Division 2.11—Group P11: specimen referred

2.11.1 Items in Group P11 not to apply in certain circumstances

(1) An item in Group P11 (Specimen referred) does not apply to a pathology service to which subsection 16A(7) of the Act applies.

(2) An item in Group P11 does not apply to a pathology service unless at least one item in Groups P1 to P8 also applies to the service.

(3) An item in Group P11 applies only to the approved pathology practitioner or approved pathology authority to whom the specimen mentioned in the item was referred.

(4) The fee mentioned in item 73940 applies only once for a single patient episode.

2.11.2 Application of an item in Group P11 to a service excludes certain other items

If item 73940 applies to a patient episode, none of the items in Group P10 apply to any pathology service rendered by the approved pathology authority or approved pathology practitioner who claimed item 73940 for the patient episode.

2.11.3 Circumstances in which an item in Group P11 does not apply

(1) An item in Group P11 does not apply to a referral if:

(a) a service for the same patient episode has been carried out by the referring approved pathology authority; and

(b) the approved pathology authority to which the referral is made is related to the referring approved pathology authority.

(2) An approved pathology authority is related to another approved pathology authority for subclause (1) if:

(a) both approved pathology authorities are employed (including employed under contract) by the same person, whether or not the person is also an approved pathology authority; or

(b) either of the approved pathology authorities is employed (including employed under contract) by the other; or

(c) both approved pathology authorities are corporations and are connected entities within the meaning of the Corporations Act 2001; or

(e) both approved pathology authorities are operated by the Commonwealth or an authority of the Commonwealth; or

(f) both approved pathology authorities are operated by the same State or internal Territory or an authority of the same State or internal Territory.

(3) An item in Group P11 does not apply to a referral if the following common tests are referred either singly or in combination (except if the following items are mentioned in combination with other items not similarly specified): 65060, 65070, 65120, 66500, 66503, 66506, 66509, 66512, 66536, 66596, 69300, 69303, 69333 or 73527.

Group P11—Specimen referred
Item	Pathology service	Fee ($)
73940	Receipt of a specimen by an approved pathology practitioner of an approved pathology authority from another approved pathology practitioner of another approved pathology authority	10.25

Division 2.12—Group P12: management of bulk‑billed services

2.12.1 Application of items 74990 and 74991

(1) Despite clause 1.2.1:

(a) if the pathology service described in item 74991 is provided to a person, either that item or item 74990, but not both those items, applies to the service; and

(b) if item 74990 or 74991 applies to a pathology service, the fee specified in that item applies in addition to the fee specified in any other item in this table that applies to the service.

(2) For items 74990 and 74991:

bulk‑billed, for a pathology service, means:

(a) a medicare benefit is payable to a person for the service; and

(b) under an agreement entered into under section 20A of the Act:

(i) the person assigns to the practitioner by whom, or on whose behalf, the service is provided, his or her right to the payment of the medicare benefit; and

(ii) the practitioner accepts the assignment in full payment of his or her fee for the service provided.

Commonwealth concession card holder means a person who is a concessional beneficiary within the meaning given by subsection 84(1) of the National Health Act 1953.

unreferred service means a pathology service that:

(a) is provided to a person by, or on behalf of, a medical practitioner, being a medical practitioner who is not a consultant physician, or specialist, in any speciality (other than a medical practitioner who is, for the purposes of the Act, both a general practitioner and a consultant physician, or specialist, in a particular speciality); and

(b) has not been referred to the medical practitioner by another medical practitioner or person with referring rights.

(3) For item 74991:

ASGC means the document titled Australian Standard Geographical Classification (ASGC) (ABS catalogue number 1216.0), published by the Australian Bureau of Statistics in July 2010.

practice location, for the provision of a pathology service, means the place of practice for which the practitioner by whom, or on whose behalf, the service is provided, has been allocated a provider number by the Chief Executive Medicare.

regional, rural or remote area means an area classified as RRMAs 3‑7 under the Rural, Remote and Metropolitan Areas Classification.

Rural, Remote and Metropolitan Areas Classification has the meaning given by the general medical services table.

SLA means a Statistical Local Area specified in the ASGC.

SSD means a Statistical Subdivision specified in the ASGC.

Group P12—Management of bulk‑billed services
Item	Pathology service	Fee ($)
74990	A pathology service to which an item in this table (other than this item or item 74991) applies if: (a) the service is an unreferred service; and (b) the service is provided to a person who is under 16 years or is a Commonwealth concession card holder; and (c) the person is not an admitted patient of a hospital; and (d) the service is bulk‑billed in respect of the fees for: (i) this item; and (ii) the other item in this table applying to the service	7.05
74991	A pathology service to which an item in this table (other than this item or item 74990) applies if: (a) the service is an unreferred service; and (b) the service is provided to a person who is under 16 years or is a Commonwealth concession card holder; and (c) the person is not an admitted patient of a hospital; and (d) the service is bulk‑billed in respect of the fees for: (i) this item; and (ii) the other item in this table applying to the service; and (e) the service is provided at, or from, a practice location in: (i) a regional, rural or remote area; or (ii) Tasmania; or (iii) a geographical area included in any of the following SSD spatial units: (A) Beaudesert Shire Part A; (B) Belconnen; (C) Darwin City; (D) Eastern Outer Melbourne; (E) East Metropolitan Perth; (F) Frankston City; (G) Gosford‑Wyong; (H) Greater Geelong City Part A; (I) Gungahlin‑Hall; (J) Ipswich City (Part in BSD); (K) Litchfield Shire; (L) Melton‑Wyndham; (M) Mornington Peninsula Shire; (N) Newcastle; (O) North Canberra; (P) Palmerston‑East Arm; (Q) Pine Rivers Shire; (R) Queanbeyan; (S) South Canberra; (T) South Eastern Outer Melbourne;	10.65
	(U) Southern Adelaide; (V) South West Metropolitan Perth; (W) Thuringowa City Part A; (X) Townsville City Part A; (Y) Tuggeranong; (Z) Weston Creek‑Stromlo; (ZA) Woden Valley; (ZB) Yarra Ranges Shire Part A; or (iv) the geographical area included in the SLA spatial unit of Palm Island (AC)

Division 2.13—Group P13: bulk billing incentive for episodes consisting of a P10 service

Note: The payments mentioned in column 3 of Group P13 are additional payments for bulk billing a patient episode consisting of a pathology service to which a Group P10 item described in column 2 applies.

Group P13—Bulk billing incentive for episodes consisting of a P10 service
Item	Pathology service	Fee ($)
74992	A patient episode that: (a) consists of a pathology service to which item 73920 applies; and (b) is bulk billed	1.60
74993	A patient episode that: (a) consists of a pathology service to which item 73922 or 73926 applies; and (b) is bulk billed	3.75
74994	A patient episode that: (a) consists of a pathology service to which item 73924 applies; and (b) is bulk billed	3.25
74995	A patient episode that: (a) consists of a pathology service to which item 73928, 73930 or 73936 applies; and (b) is bulk billed	4.00
74996	A patient episode that: (a) consists of a pathology service to which item 73932 or 73940 applies; and (b) is bulk billed	3.70
74997	A patient episode that: (a) consists of a pathology service item 73934 applies; and (b) is bulk billed	3.30
74998	A patient episode that: (a) consists of a pathology service to which item 73938 applies; and (b) is bulk billed	2.00
74999	A patient episode that: (a) consists of a pathology service to which item 73923, 73925, 73927, 73929, 73931, 73933, 73935, 73937 or 73939 applies; and (b) is bulk billed	1.60

Part 3—Abbreviations

Note: A service or drug that is not mentioned in this Part must be written in full.

Abbreviations
Test	Abbreviation	Item
Abnormal haemoglobins	AH	65117
Acetoacetate	ACAT	66500
Acetylcholine receptor—tissue antigens—antibodies	ARA	71165
Acid phosphatase	ACP	66500
Actinomycetes—microbial antibody testing	ACT	69384
Activated protein C resistance	APC	65142, 65171, 65175–65179
Adenovirus—microbial antibody testing	ADE	69384
Adrenal cortex—tissue antigens—antibodies	ADR	71165
Adrenocorticotrophic hormone (ACTH)	ACTH	66695
AFB microscopy and culture of sputum—one specimen	AFB1	69324
AFB microscopy and culture of sputum—2 specimens	AFB2	69327
AFB microscopy and culture of sputum—3 specimens	AFB3	69330
Alanine aminotransferase	ALT	66500
Albumin	ALB	66500
Alcohol (ethanol)	ETOH	66626, 66800
Aldosterone	ALDS	66695
Alkaline phosphatase	ALP	66500
Alkaline phosphatase—isoenzymes	ALPI	66641
Alpha‑1‑antitrypsin	AAT	66635
Alpha‑fetoprotein	AFP	66650–66653, 66743, 66750, 66751
Aluminium	AL	66825, 66828
Aluminium—renal dialysis	ALR	66671
Amikacin		66800
Amino acids	AA	66752
Amiodarone	AMIO	66812
Amitriptyline	AMIT	66812
Ammonia	NH3	66500
Amniotic fluid examination	AFE	66749
Amylase	AMS	66500
Amylobarbitone	AMYL	66812
Androstenedione	ANDR	66695
Angiotensin converting enzyme	ACE	66758
Antibiotic and antimicrobial chemotherapeutic agents—quantitation	QAA	66800, 66812
Antibodies to extractable nuclear antigens—characterisation of antibodies if positive ENA	ENAP	71103
Antibodies to extractable nuclear antigens—detection	ENA	71101
Antibodies to nuclear antigens—detection	ANA	71097
Antibodies to nuclear antigens—quantitation and measurement of DNA binding if positive ANA	ANAP	71099
Antibodies to tissue antigens—acetylcholine receptor	ARA	71165
Antibodies to tissue antigens—adrenal cortex	ADR	71165
Antibodies to tissue antigens—ANCA‑myeloperoxidase	MPO	71153
Antibodies to tissue antigens—ANCA‑PR3	PR3	71153
Antibodies to tissue antigens—anti‑actin	AACT	71119
Antibodies to tissue antigens—anti‑endomysial	EMA	71163
Antibodies to tissue antigens—cardiolipin	ACL	71165
Antibodies to tissue antigens—coeliac disease panel	CLC	71163, 71164
Antibodies to tissue antigens—gastric parietal cell	PCA	71119
Antibodies to tissue antigens—gliadin IgA	GLIA	71163
Antibodies to tissue antigens—gliadin IgG	GLIG	71163
Antibodies to tissue antigens—glomerular basement membrane	GBM	71153
Antibodies to tissue antigens—heart	AHE	71165
Antibodies to tissue antigens—histone	AHI	71165
Antibodies to tissue antigens—insulin receptor antibodies	INSA	71165
Antibodies to tissue antigens—intercellular cement substance of skin	ICCS	71165
Antibodies to tissue antigens—intrinsic factor	AIF	71165
Antibodies to tissue antigens—islet cell	AIC	71165
Antibodies to tissue antigens—Jo‑1	JO1	71119
Antibodies to tissue antigens—keratin	KERA	71119
Antibodies to tissue antigens—liver/kidney microsomes	LKA	71119
Antibodies to tissue antigens—lymphocyte	ALY	71165
Antibodies to tissue antigens—mitochondria	MA	71119
Antibodies to tissue antigens—neuron	ANE	71165
Antibodies to tissue antigens—neutrophil cytoplasm	ANCA	71153
Antibodies to tissue antigens—ovary	AOV	71165
Antibodies to tissue antigens—parathyroid	PTHA	71165
Antibodies to tissue antigens—platelet	APA	71165
Antibodies to tissue antigens—PM‑Sc1	PM1	71119
Antibodies to tissue antigens—reticulin	RCA	71119
Antibodies to tissue antigens—salivary gland	ASG	71165
Antibodies to tissue antigens—Scl‑70	SCL	71119
Antibodies to tissue antigens—skeletal muscle	SLA	71165
Antibodies to tissue antigens—skin basement membrane	SKA	71165
Antibodies to tissue antigens—smooth muscle	SMA	71119
Antibodies to tissue antigens—thyroglobulin	ATG	71165
Antibodies to tissue antigens—thyroid microsome	TMA	71165
Antibodies to tissue antigens—tissue transglutaminase	TTG	71163
Antibodies to tissue antigens—TSH receptor antibody test	TSHA	71165
Antibody testing, microbial (see Microbial)
Antigen testing, microbial (see Microbial)
Antithrombin III	ATH	65142, 65171, 65175–65179
Anti‑Xa activity	QAXA	65147
Anus—cytology on specimens from	SMCY	73043
Apolipoprotein B/A1 ratio	APO	66536
Arsenic	AS	66825, 66828
Aspartate aminotransferase	AST	66500
Aspergillus—microbial antibody testing	ASP	69384
Avian precipitins (bird fancier’s disease)—microbial antibody testing	APP	69384
B12 vitamin	B12	66838
Barbiturate	BARB	66800, 66812
Beryllium	BE	66825, 66828
Beta‑2‑microglobulin	BMIC	66629
Beta‑hydroxybutyrate	BHYB	66500
Bicarbonate	HCO3	66500
Bilirubin (all fractions)	BILI	66500
Bilirubin (all fractions)—in urine	UBIL	66500
Bilirubin (all fractions)—neonatal	BILN	66749
Bird fancier’s disease (see avian precipitins)	APP	69384
Blastomyces—microbial antibody testing	BLM	69384
Blood—compatibility testing	XMAT	65099–65108
Blood—culture	BC	69354–69360
Blood—faecal occult	FOB	66764–66770
Blood—film	BF	65066
Blood—full examination	FBE	65070
Blood—gases	GAS	66566
Blood—group and blood group antibodies	BGAB	65096
Blood—group antibodies	BGA	65111
Blood—group systems	BGS	65093
Blood—grouping—ABO and RH (D antigen)	BG	65090
Blood—viscosity	VISC	65060
Body cavities—aspirations of—microscopy and culture of material from	MCPO	69321
Body fluids—cytology	BFCY	73045
Bone—low mineral densities	CBLB	66773
Bone—metabolic bone disease	CBMB	66776
Bone marrow examination—aspirate	BMEA	65087
Bone marrow examination—trephine	BMET	65084
Bordetella pertussis—microbial antibody testing	BOR	69384
Borrelia burgdorferi—microbial antibody testing	BOB	69384
Breath hydrogen test	BHT	66674
Bromide	BRMD	66812
Brucella—microbial antibody testing	BRU	69384
C‑l esterase inhibitor—functional	CEIF	66647
C‑l esterase inhibitor—quantitation	CEIQ	66644
CA‑15.3 antigen	CA15	66650
CA‑19.9 antigen	CA19	66650
CA‑125 antigen	C125	66650
Cadmium	CD	66825, 66828
Caeruloplasmin	CPLS	66632
Calcitonin	CALT	66695
Calcium—ionised	ICA	66584
Calcium (total or corrected for albumin)	CA	66500
Calculus analysis	CALC	66590
Campylobacter jejuni—microbial antibody testing	CAM	69384
Candida—microbial antibody testing	CAN	69384
Carbamazepine (Tegretol)	CARB	66800
Carboxyhaemoglobin	COHB	65117
Carcinoembryonic antigen	CEA	66650
Cardiac enzymes	CE	66506
Cardiolipin—tissue antigens—antibodies	ACL	71165
Catecholamines	CAT	66779
Cell‑mediated immunity—delayed type—hypersensitivity test	CMI	71137
Cell‑mediated immunity in blood	CMIB	69471
Cervix—cytology—abnormalities	CCRA	73055
Cervix—cytology—routine	CCR	73053
Cervix—microscopy and culture of material from	MCGR	69312
Characterisation of antibodies if positive ENA	ENAP	71103
Chemicals, toxic (ingested or absorbed)—assays	DRGO	66623
Chlamydia—investigation by any method	CHLM	69494
Chlamydia—investigation by any method and N gonorrhoea by NAA methods	CHGO	69494
Chlamydia—microbial antibody testing	CHL	69384
Chlamydia—microbial antigen testing	MCCH	69494
Chloral hydrate	CHHY	66812
Chlorazepate	CHZP	66812
Chloride	CL	66500
Chloroquine	CLOQ	66812
Chlorpromazine	CHLO	66812
Cholesterol	CHOL	66500
Cholesterol—HDL	HDLC	66536
Cholinesterase	CHSE	66758
Chorionic gonadotrophin—detection for pregnancy diagnosis	HCGP	73527–73529
Chorionic gonadotrophin—quantitation	HCG	66650–66653, 66750, 66751, 73529
Chromium	CR	66825, 66828
Chromosome identification and banding		73287–73289
Chromosome identification—studies—blood	CSB	73289
Chromosome identification—studies—other than blood	CS	73287
Cimetidine	CMTD	66812
Clobazam	CLOB	66812
Clomipramine	CLOM	66812
Clonazepam (Rivotril)	CLON	66812
Clostridium difficile—microbial antigen testing	CLDT	69363
Coagulation factor inhibitors by Bethesda assay	BETH	65159
Coagulation—factors (see individual factors)
Coagulation—studies	COAG	65120
Coccidioides—microbial antibody testing	CCC	69384
Coeliac antibodies	CLC	71163, 71164
Cold agglutinins	CAG	65114
Collagen—low bone	CBLB	66773
Collagen—metabolic disease	CBMB	66776
Compatibility testing	XMAT	65099–65108
Complement, total haemolytic	COM	71081
Complement, total haemolytic—components C3	C3	71083
Complement, total haemolytic—components C4	C4	71083
Complement, total haemolytic—other components	COMP	71089
Complement, total haemolytic—properdin factor B	PFB	71083
Copper	CU	66819, 66822
Cortisol	CORT	66695
Cortisol in saliva	CORS	66711, 66712
Coxsackie B1‑6—microbial antibody testing	COX	69384
C‑Peptide	CPEP	66695
C‑reactive protein	CRP	66500
Creatine kinase	CK	66500
Creatine kinase—isoenzymes	CKI	66518
Creatine kinase—isoenzymes (electrophoresis)	CKIE	66518
Creatinine	C	66500
Cryofibrinogen—detection and quantitation	CFID	71064
Cryoglobulins—characterisation by electrophoresis and immunoelectrophoresis or immunofixation or isoelectric focusing	RYO	71059
Cryoglobulins—detection and quantitation	CGLD	71064
Cryptococcal antigen—microbial antigen testing	CRYN	69494
Cryptococcus—microbial antibody testing	CRY	69384
CSF antigens—group B streptococcus	STB	69494
CSF antigens—Haemophilus influenzae	HI	69494
CSF antigens—Neisseria meningitidis	NMG	69494
CSF antigens—Streptococcus pneumoniae	SPN	69494
CSF—microscopy and culture of material from	MCPO	69321
Cultural examination of faeces	FCS	69345
Cyclic AMP	CAMP	66695
Cyclosporin A	CLSA	66812
Cystine—qualitative	UCYS	66752
Cystine—quantitative	CYST	66752
Cytology—fine needle aspiration of solid tissues	FNCY	73049
Cytology—fine needle aspiration of solid tissues—aspiration or attendance by a pathologist	FNCP	73051
Cytology—from 3 sputum or urine specimens	SPCY	73047
Cytology—from body fluids, sputum (one specimen), urine, washings or brushings	BFCY	73045
Cytology—from cervix—abnormalities	CCRA	73055
Cytology—from cervix—routine	CCR	73053
Cytology—from skin, nipple discharge, lip, mouth, nose or anus	SMCY	73043
Cytology—from vagina	CVO	73057
Cytomegalovirus—microbial antibody testing	CMV	69384
Cytomegalovirus serology in pregnancy—microbial antibody testing	CMVP	69405–69411
D‑dimer test	DD	65120
D vitamin	VITD	66833
Dehydroepiandrosterone sulphate (DHEAS)	DHEA	66695
Dengue—microbial antibody testing	DEN	69384
11‑Deoxycortisol	DCOR	66695
Desipramine	DESI	66812
Dexamethasone	DXST	66686
Dexamethasone—suppression test	DEXA	66686
DHEAS (Dehydroepiandrosterone sulphate)	DHEA	66695
Diazepam	DIAZ	66812
Differential cell count	DIFF	65070
Digoxin	DIG	66800
Dihydrotestosterone	DHTS	66695
Diphenylhydantoin (Dilantin)	DIL	66812
Diphtheria—microbial antibody testing	DIP	69384
Direct Coombs test	CMBS	65114
Disopyramide (Rythmodan)	DISO	66800
DNA binding—quantitation and measurement if positive ANA	ANAP	71099
DNA (double‑stranded DNA) antibody	DSDNA	71099
Donath Landsteiner antibody test	DLAT	65075
Down’s syndrome and neural tube defects	NTDD	66750, 66751
Doxepin hydrochloride	DOXE	66812
Drugs—abuse treatment programme—assay	DATP	66626
Drugs—inappropriate dosage—assay	DRGO	66623
Drugs—therapeutic—assay (see individual drugs)		66800, 66812
Dynamic function tests	GHSE	66686
Ear—microscopy and culture of material from	MCSW	69303
Echinococcus—microbial antibody testing	ECC	69384
Echis test	ECHI	65120
ECHO‑coxsackie group—microbial antibody testing	ECH	69384
Electrolytes	E	66509
Electron microscopy of biopsy material	EM	72851, 72852
Electrophoresis, and immunofixation or immunoelectrophoresis or isoelectric focusing—characterisation of cryoglobulins	RYO	71059
Electrophoresis, and immunofixation or immunoelectrophoresis or isoelectric focusing—characterisation of paraprotein	PRYO	71059
Electrophoresis, to demonstrate—creatine kinase isoenzymes	CKIE	66518
Electrophoresis, to demonstrate—lactate dehydrogenase isoenzymes	LDI	66641
Electrophoresis, to demonstrate—lipoprotein subclasses	LEPG	66539
Electrophoresis, to demonstrate—quantitation of protein classes, or paraprotein	EPPI	71057, 71058
Elements (see individual elements)
Endomysium antibodies	EMA	71163
Entamoeba histolytica—microbial antibody testing	AMO	69384
Enzyme assays of solid tissue or tissues	ENZS	66683
Enzyme histochemistry of skeletal muscle	EHSK	72844
Eosinophil cationic protein	ECP	71095
Epstein Barr virus—microbial antibody testing	EBV	69472–69474
Erythrocyte—assessment of haemolysis	ERYH	65075
Erythrocyte—assessment of metabolic enzymes	ERYM	65075
Erythrocyte—count	RCC	65070
Erythrocyte—sedimentation rate	ESR	65060
Ethanol (alcohol)	ETOH	66626, 66800
Ethosuximide (Zarontin)	ETHO	66800
Extractable nuclear antigens—detection of antibodies to	ENA	71101
Eye—microscopy and culture of material from	MCSW	69303
Factor II	FII	65150
Factor V	FV	65150
Factor V Leiden mutation	FVLM	73308, 73311
Factor VII	FVII	65150
Factor VIII	VIII	65150
Factor IX	FIX	65150
Factor X	FX	65150
Factor XI	FXI	65150
Factor XII	FXII	65150
Factor XIII	XIII	65150
Factor XIII deficiency test	F13D	65120
Faecal antigen test for Helicobacter pylori	FAHP	69494
Faecal blood	FOB	66764–66770
Faecal fat	FFAT	66674
Faecal fat—haemoglobin	FFH	66764
Faecal fat—reducing substances	FRS	66761
Faeces—culture	FCS	69345
Faeces—microscopy for parasites	OCP	69336–69339
Ferritin (see also Iron studies)	FERR	66593
Fibrin monomer	FM	65120
Fibrinogen	FIB	65120
Fibrinogen—degradation products	FDP	65120
Fitzgerald factor	FGF	65150
Flecainide	FLEC	66812
Fletcher factor	FF	65150
Fluorescent treponemal antibody—absorption test (FTA‑ABS)—microbial antibody testing	FTA	69384
Fluoxetine	FLUX	66812
Foetal red blood cells—Kliehauer	KLEI	65162
Folate—serum	SF	66840
Follicle stimulating hormone (FSH)	FSH	66695
Fragile X	FXS	73300, 73305
Frozen section diagnosis of biopsy material	FS	72855, 72856
Fructosamine	FRUC	66557
Full blood examination	FBE	65070
Gamma glutamyl transpeptidase	GGT	66500
Gastric parietal cell—tissue antigens—antibodies	PCA	71119
Gastrin	GAST	66695
Gentamicin		66800
Gliadin IgA—tissue antigens—antibodies	GLIA	71163
Globulin	GLOB	66500
Glomerular basement membrane—tissue antigens—antibodies	GBA	71165
Glucagon	GLGO	66695
Glucose	GLUC	66500
Glucose—tolerance test	GTT	66542
Glycosylated haemoglobin (Hb Alc)	GHB	66551
Gold	AU	66825, 66828
Group B streptococcus—CSF antigens	STB	69494
Group B streptococcus—microbial antigen testing	STB	69494
Group P9—simple basic pathology tests		73801–73811
Growth hormone	GH	66695
Growth hormone—stimulation by exercise or L‑dopa	GHSE	66686
Growth hormone—suppression by dexamethasone or glucose	GHSG	66686
Haematocrit	HCT	65070
Haemochromatosis	FEUP	73317
Haemoglobin	HB	65060
Haemoglobinopathy tests	HMGP	65081
Haemophilus influenzae—CSF antigens	HI	69494
Haemophilus influenzae—microbial antibody testing	HUS	69384
Haemophilus influenzae—microbial antigen testing	HI	69494
Haloperidol	HALO	66812
Haptoglobins	HGLB	66632
HDL cholesterol	HDLC	66536
Heart—tissue antigens—antibodies	AHE	71165
Heparin—test	HEPR	65144
Hepatitis B or C confirmatory test	HSVP	69484
Hepatitis C—detection	RNAC	69499
Hepatitis C—genotype	GHCV	69491
Hepatitis C—quantitation	THCV	69488
Hepatitis investigation—3 markers	HEP3	69481
Hepatitis serology—in pregnancy	HEPP	69405–69413
Hepatitis status or carriage—one marker	HEP1	69475
Hepatitis status or carriage—2 markers	HEP2	69478
Hepatitis status or carriage—3 markers	HEP3	69481
Herpes simplex virus—direct detection from clinical material	HSV	69494
Herpes simplex virus—investigation by culture	HSVC	69494
Herpes simplex virus—microbial antibody testing	HPA	69384
Herpes simplex virus—microbial antigen testing	HSV	69494
Heterophil antibodies	IM	65114
HIAA (hydroxyindoleacetic acid)	HIAA	66779
Histamine	HIAM	66779
Histone—tissue antigens—antibodies	AHI	71165
Histopathology of biopsy material	HIST	72813–72836
Histoplasma—microbial antibody testing	HIP	69384
HIV—antiretroviral therapy	TVLT	69381
HIV—cerebrospinal fluid	CVLT	69382
HIV—monitoring	MVLT	69378
HLA typing—HLA class 1	HLA1	71149
HLA typing—HLA class 2	HLA2	71151
HLA typing—HLA‑B27	HLAB	71147
HMMA (hydroxy‑3‑methoxymandelic acid, previously known as VMA)	HMMA	66779
HMPG (hydroxy‑methoxy phenylethylene glycol)	HMPG	66779
Homovanillic acid	HVA	66779
Hormone receptor assay—breast	HRA	66662
Hormone receptor assay—ovary	HRO	66662
Hormones—11 deoxycortisol	DCOR	66695
Hormones—adrenocorticotrophic hormone	ACTH	66695
Hormones—aldosterone	ALDS	66695
Hormones and hormone binding proteins (see individual hormones and proteins)		66695
Hormones—androstenedione	ANDR	66695
Hormones—calcitonin	CALT	66695
Hormones—cortisol	CORT	66695
Hormones—C‑Peptide	CPEP	66695
Hormones—cyclic AMP	CAMP	66695
Hormones—dehydroepiandrosterone sulphate (DHEAS)	DHEA	66695
Hormones—dihydrotestosterone	DHTS	66695
Hormones—follicle stimulating hormone	FSH	66695
Hormones—gastrin	GAST	66695
Hormones—glucagon	GLGO	66695
Hormones—growth hormone	GH	66695
Hormones—growth hormone—stimulation by exercise or L‑dopa	GHSE	66686
Hormones—growth hormone—suppression by dexamethasone or glucose	GHSG	66686
Hormones—hormone receptor assay—breast	HRA	66662
Hormones—hormone receptor assay—ovary	HRO	66662
Hormones—human chorionic gonadotrophin—detection for pregnancy diagnosis	HCGP	73527, 73529
Hormones—human chorionic gonadotrophin—quantitation	HCG	66650–66653, 66750, 66751, 73529
Hormones—hydroxyprogesterone	OHP	66695
Hormones—insulin	INS	66695
Hormones—luteinizing hormone	LH	66695
Hormones—oestradiol	E2	66695
Hormones—oestriol	E3	66750, 66751
Hormones—oestrone	E1	66695
Hormones—parathyroid hormone	PTH	66695
Hormones—progesterone	PROG	66695
Hormones—prolactin	PROL	66695
Hormones—renin	REN	66695
Hormones—sex hormone binding globulin	SHBG	66695
Hormones—somatomedin	SOMA	66695
Hormones—stimulation by exercise or L‑dopa	GHSE	66686
Hormones—suppression by dexamethasone or glucose	GHSG	66686
Hormones—testosterone	TES	66695
Hormones—urine steroid fraction or fractions	USF	66695
Hormones—vasoactive intestinal peptide	VIP	66695
Hormones—vasopressin	ADH	66695
Huhner’s test	HT	73521
Human chorionic gonadotrophin—detection for pregnancy diagnosis	HCGP	73527, 73529
Human chorionic gonadotrophin—quantitation	HCG	66650–66653, 66750, 66751, 73529
Human papillomaviruses	HPV	69418
HVA (homovanillic acid)	HVA	66779
Hydatid—microbial antibody testing	HYD	69384
Hydroxy‑3‑methoxymandelic acid (previously known as VMA)	HMMA	66779
Hydroxychloroquine	HOCQ	66812
Hydroxyindoleacetic acid	HIAA	66779
Hydroxy methoxy phenylethylene glycol	HMPG	66779
Hydroxyprogesterone	OHP	66695
Hydroxyproline	HYDP	66752
Imipramine	IMIP	66812
Immediate frozen section diagnosis of biopsy material	FS	72855–72856
Immunocyto. one‑3 antibodies	ICC	73059, 73061
Immunocyto. 4+ antibodies	ICC1	73060
Immunoelectrophoresis and electrophoresis—characterisation of cryoglobulins	RYO	71059
Immunoelectrophoresis and electrophoresis—characterisation of paraprotein	PPRO	71059
Immunoglobulins—A	IGA	71066
Immunoglobulins—D	IGD	71074
Immunoglobulins—E (total)	IGE	71075–71079
Immunoglobulins—G	IGG	71068
Immunoglobulins—G, 4 subclasses	SIGG	71073
Immunoglobulins—M	IGM	71072
Immunohistochemical investigation of biopsy material	HIS	72846–72848
Infectious mononucleosis	IM	69384
Influenza A—microbial antibody testing	FLA	69384
Influenza B—microbial antibody testing	FLB	69384
Insulin	INS	66695
Insulin receptor antibodies—tissue antigens—antibodies	INSA	71165
Insulin—tissue antigens—antibodies	AINS	71165
Intercellular cement substance of skin—tissue antigens—antibodies	ICCS	71165
Intestinal disaccharidases	INTD	66680
Intrinsic factor—tissue antigens—antibodies	AIF	71165
Iron studies (iron, transferrin and ferritin)	IS	66596
Islet cell—tissue antigens—antibodies	AIC	71165
Isoelectric focusing and electrophoresis—characterisation of cryoglobulins	RYO	71059
Isoelectric focusing and electrophoresis—characterisation of paraprotein	PPRO	71059
Jo—1—tissue antigens—antibodies	JO1	71119
Keratin—tissue antigens—antibodies	KERA	71119
Kleihauer test	KLEI	65162
Lactate	LACT	66500
Lactate—dehydrogenase	LDH	66500
Lactate—dehydrogenase isoenzymes	LDI	66641
Lamellar body phospholipid	LBPH	66749
Lead	PB	66665
Lecithin/sphingomyelin ratio (amniotic fluid)	LS	66749
Legionella pneumophila—serogroup 1—microbial antibody testing	LP1	69384
Legionella pneumophila—serogroup 2—microbial antibody testing	LP2	69384
Leishmaniasis—microbial antibody testing	LEI	69384
Leptospira—microbial antibody testing	LEP	69384
Leucocyte count	WCC	65070
Leucocyte count—3 surface markers—blood, CSF, serous fluid	LMH3	71139
Leucocyte count—3 surface markers—tissue	LMT3	71141
Leucocyte count—6 surface markers—blood, CSF, serous fluid and tissue(s)	LMHT	71145
Leucocyte count—6 surface markers—blood, CSF, serous fluid or tissue	LM6	71143
Leucocyte count—CD34 surface marker only—blood	LMCD34	71146
Lignocaine	LIGN	66800
Lip—cytology on specimens from	SMCY	73043
Lipase	LIP	66500
Lipid studies	FATS	66500
Lipoprotein subclasses—electrophoresis	LEPG	66539
Listeria—microbial antibody testing	LIS	69384
Lithium	LI	66800
Liver function tests	LFT	66515
Liver/kidney microsomes—tissue antigens—antibodies	LKA	71119
Lupus anticoagulant	LUPA	65137, 65142, 65175–65179
Luteinizing hormone	LH	66695
Lymphocyte—tissue antigens—antibodies	ALY	71165
Lymphocytes—functional tests—one test	LF1	71127
Lymphocytes—functional tests—2 tests	LF2	71129
Lymphocytes—functional tests—3 tests	LF3	71131
Magnesium	MG	66500
Mammary serum antigen	MSA	66650
Manganese	MN	66819, 66822
Mantoux test	MANT	73811
Measles—microbial antibody testing	MEA	69384
Mercury	HG	66825, 66828
Metabolic bone disease	CBMB	66776
Metanephrines	MNEP	66779
Methadone	MTDN	66812
Methaemalbumin detection (Schumm’s test)	SCHM	65117
Methotrexate	MTTA	66812
Methsuximide	MSUX	66812
Methylphenobarbitone	MPBT	66812
Metronidazole	MRDZ	66812
Mexiletine (Mexitil)	MEX	66812
Mianserin	MIAS	66812
Microalbumin	MALB	66560
Microbial antibody testing—actinomycetes	ACT	69384
Microbial antibody testing—adenovirus	ADE	69384
Microbial antibody testing—aspergillus	ASP	69384
Microbial antibody testing—avian precipitins (bird fancier’s disease)	APP	69384
Microbial antibody testing—Blastomyces	BLM	69384
Microbial antibody testing—Bordetella pertussis	BOR	69384
Microbial antibody testing—Borrelia burgdorferi	BOB	69384
Microbial antibody testing—Brucella	BRU	69384
Microbial antibody testing—Campylobacter jejuni	CAM	69384
Microbial antibody testing—Candida	CAN	69384
Microbial antibody testing—Chlamydia	CHL	69384
Microbial antibody testing—Coccidioides	CCC	69384
Microbial antibody testing—Coxsackie B1‑6	COX	69384
Microbial antibody testing—Cryptococcus	CRY	69384
Microbial antibody testing—cytomegalovirus	CMV	69384
Microbial antibody testing—cytomegalovirus serology in pregnancy	CMVP	69384
Microbial antibody testing—dengue	DEN	69384
Microbial antibody testing—diphtheria	DIP	69384
Microbial antibody testing—echinococcus	ECC	69384
Microbial antibody testing—echo‑coxsackie group	ECH	69384
Microbial antibody testing—Entamoeba histolytica	AMO	69384
Microbial antibody testing—Epstein Barr virus	EBV	69472–69474
Microbial antibody testing—fluorescent treponemal antibody—absorption test (FTA‑ABS)	FTA	69384
Microbial antibody testing—Haemophilus influenzae	HUS	69384
Microbial antibody testing—herpes simplex virus	HPA	69384
Microbial antibody testing—Histoplasma	HIP	69384
Microbial antibody testing—Human Immunodeficiency Virus		69384
Microbial antibody testing—hydatid	HYD	69384
Microbial antibody testing—infectious mononucleosis	IM	69384
Microbial antibody testing—influenza A	FLA	69384
Microbial antibody testing—influenza B	FLB	69384
Microbial antibody testing—Legionella pneumophila—serogroup 1	LP1	69384
Microbial antibody testing—Legionella pneumophila—serogroup 2	LP2	69384
Microbial antibody testing—leishmaniasis	LEI	69384
Microbial antibody testing—Leptospira	LEP	69384
Microbial antibody testing—Listeria	LIS	69384
Microbial antibody testing—measles	MEA	69384
Microbial antibody testing—Micropolyspora faeni	MIC	69384
Microbial antibody testing—mumps	MUM	69384
Microbial antibody testing—Murray Valley encephalitis	MVE	69384
Microbial antibody testing—Mycoplasma pneumoniae	MYC	69384
Microbial antibody testing—Neisseria meningitidis	MEN	69384
Microbial antibody testing—Newcastle disease	NCD	69384
Microbial antibody testing—parainfluenza 1	PF1	69384
Microbial antibody testing—parainfluenza 2	PF2	69384
Microbial antibody testing—parainfluenza 3	PF3	69384
Microbial antibody testing—paratyphi	PTY	69384
Microbial antibody testing—pertussis	PER	69384
Microbial antibody testing—poliomyelitis	PLO	69384
Microbial antibody testing—Proteus OX 19	POX	69384
Microbial antibody testing—Proteus OXK	POK	69384
Microbial antibody testing—Q fever	QFF	69384
Microbial antibody testing—rapid plasma reagin test	RPR	69384
Microbial antibody testing—respiratory syncytial virus	RSV	69384
Microbial antibody testing—Ross River virus	RRV	69384
Microbial antibody testing—rubella	RUB	69384
Microbial antibody testing—Salmonella typhi (H)	SAH	69384
Microbial antibody testing—Salmonella typhi (O)	SAO	69384
Microbial antibody testing—Schistosoma	STO	69384
Microbial antibody testing—streptococcal serology—anti‑DNASE B titre	ADNB	69384
Microbial antibody testing—streptococcal serology—anti‑streptolysin O titre	ASOT	69384
Microbial antibody testing—Streptococcus pneumoniae	PCC	69384
Microbial antibody testing—tetanus	TET	69384
Microbial antibody testing—Thermoactinomyces vulgaris	THE	69384
Microbial antibody testing—thermopolyspora	TPS	69384
Microbial antibody testing—Toxocara	TOC	69384
Microbial antibody testing—Toxoplasma	TOX	69384
Microbial antibody testing—TPHA (Treponema pallidum haemagglutination test)	TPHA	69384
Microbial antibody testing—Treponema pallidum haemagglutination test	TPHA	69384
Microbial antibody testing—trichinosis	TOS	69384
Microbial antibody testing—typhus, Weil‑Felix	TYP	69384
Microbial antibody testing—Varicella zoster	VCZ	69384
Microbial antibody testing—VDRL (Venereal Disease Research Laboratory)	VDRL	69384
Microbial antibody testing—Yersinia enterocolitica	YER	69384
Microbial antigen testing—Chlamydia	MCCH	69494
Microbial antigen testing—Clostridium difficile	CLDT	69363
Microbial antigen testing—group B streptococcus	STB	69494
Microbial antigen testing—Haemophilus influenzae	HI	69494
Microbial antigen testing—herpes simplex virus	HSV	69494
Microbial antigen testing—Neisseria gonorrhoeae	GON	69494
Microbial antigen testing—Neisseria meningitidis	NMG	69494
Microbial antigen testing—respiratory syncytial virus	RSVN	69494
Microbial antigen testing—Streptococcus pneumonia	SPN	69494
Microbial antigen testing—Varicella zoster	VCZN	69494
Micropolyspora faeni	MIC	69384
Microscopic examination of—faeces for parasites	OCP	69336–36939
Microscopic examination of—wet film material other than blood	MWFM	69300
Microscopy and culture of—material from nose, throat, eye or ear	MCSW	69303
Microscopy and culture of—material from skin	MCSK	69309
Microscopy and culture of—postoperative wounds, aspirates of body cavities	MCPO	69321
Microscopy and culture of—specimens of sputum	MCSP	69318
Microscopy and culture of—specimens of sputum, urine or other body fluids for mycobacteria—one specimen	AFB1	69324
Microscopy and culture of—specimens of sputum, urine or other body fluids for mycobacteria—2 specimens	AFB2	69327
Microscopy and culture of—specimens of sputum, urine or other body fluids for mycobacteria—3 specimens	AFB3	69330
Microscopy and culture of—superficial sites	MCSS	69306
Microscopy and culture of—urethra, vagina, cervix or rectum	MCGR	69312
Microscopy and culture to detect pathogenic micro‑organisms including Chlamydia	MCCH	69494
Microscopy, culture, identification and sensitivity of urine	UMCS	69333
Mitochondria—tissue antigens—antibodies	MA	71119
Mouth—cytology on specimens from	SMCY	73043
Mumps—microbial antibody testing	MUM	69384
Murray Valley encephalitis—microbial antibody testing	MVE	69384
Mycobacteria microscopy and culture of sputum—one specimen	AFB 1	69324
Mycobacteria microscopy and culture of sputum—2 specimens	AFB 2	69327
Mycobacteria microscopy and culture of sputum—3 specimens	AFB 3	69333
Mycoplasma pneumoniae—microbial antibody testing	MYC	69384
Myoglobin	MYOG	66518
N‑acetyl procainamide	NAPC	66812
Neisseria gonorrhoeae by NAA techniques and chlamydia by any method	CHGO	69494
Neisseria gonorrhoeae—microbial antigen testing	GON	69494
Neisseria meningitidis—antigens	NMG	69494
Neisseria meningitidis—microbial antibody testing	MEN	69384
Neisseria meningitidis—microbial antigen testing	NMG	69494
Netilmicin		66800
Neural tube defects and Down’s syndrome	NTDD	66750, 66751
Neuron—tissue antigens—antibodies	ANE	71165
Neutrophil cytoplasm—tissue antigens—antibodies	ANCA	71165
Neutrophil functions	NFT	71135
Newcastle disease—microbial antibody testing	NCD	69384
Nickel	NI	66825, 66828
Nipple discharge—cytology on specimens from	SMCY	73043
Nitrazepam	NITR	66812
Nordothiepin	NDIP	66812
Norfluoxetine	NFLE	66812
Nortriptyline	NORT	66812
Nose—cytology on specimens from	SMCY	73043
Nose—microscopy and culture of material from	MCSW	69303
Nuclear antigens—detection of antibodies to	ANA	71097
Oestradiol	E2	66695
Oestriol	E3	66750, 66751
Oestrone	E1	66695
Oligoclonal proteins	OGP	71062
Op/biopsy specimens—microscopy and culture of material from	MCPO	69321
Oral glucose challenge test—gestational diabetes	OGCT	66545
Oral glucose tolerance test—gestational diabetes	GTTP	66542
Osmolality, serum or urine	OSML	66563
Ovary—tissue antigens—antibodies	AOV	71165
Oxalate	OXAL	66752
Oxazepam	OXAZ	66812
PAA (phenyl acetic acid)	PAA	66779
Palmitic acid in amniotic fluid	PALM	66749
Pap smear	CCR	73053
Papanicolaou test	CCR	73053
Paracetamol	PARA	66800
Parainfluenza 1—microbial antibody testing	PF1	69384
Parainfluenza 2—microbial antibody testing	PF2	69384
Parainfluenza 3—microbial antibody testing	PF3	69384
Paraprotein characterisation—by electrophoresis and immunoelectrophoresis or immunofixation or isoelectric focusing	PPRO	71059
Paraprotein characterisation—on concurrently collected serum or urine	PPSU	71060
Paraprotein quantitation—by electrophoresis	EPPI	71057
Paraquat	PARQ	66812
Parasites—microscopic examination of faeces	OCP	69336–69339
Parathyroid hormone (PTH)	PTH	66695
Parathyroid—tissue antigens—antibodies	PTHA	71165
Paratyphi—microbial antibody testing	PTY	69384
Partial thromboplastin time	PTT	65120
Patient episode initiation fees	PEI	73922–73939
Pentobarbitone	PENT	66812
Perhexiline	PHEX	66812
Pertussis—microbial antibody testing	PER	69384
Phenobarbitone	PHBA	66800
Phensuximide	PHEN	66812
Phenylacetic acid	PAA	66779
Phenytoin	PHEY	66800
Phosphate	PHOS	66500
Phosphatidylglycerol	PTGL	66749
Platelet—aggregation	PLTG	65144
Platelet—count	PLTC	65070
Platelet—tissue antigens—antibodies	APA	71165
PM‑Sc1—tissue antigens—antibodies	PM1	71119
Poliomyelitis—microbial antibody testing	PLO	69384
Porphobilinogen in urine	UPG	66782
Porphyrins in urine—qualitative test	UPR	66782
Porphyrins—quantitative test, one or more fractions	PR	66785
Potassium	K	66500
Prealbumin	PALB	66632
Prednisolone	PRED	66812
Pregnancy serology—one test	MSP1	69405
Pregnancy serology—2 tests	MSP2	69408
Pregnancy serology—3 tests	MSP3	69411
Pregnancy serology—4 tests	MSP4	69413
Pregnancy testing		73806
Pregnancy testing—diagnosis of Down’s syndrome and neural tube defect	NTDD	66750, 66751
Pregnancy testing—HCG detection	HCG	73527, 73529
Pregnancy testing—HCG quantitation	HCG	73529
Primidone	PRIM	66800
Procainamide	PCAM	66800
Progesterone	PROG	66695
Prolactin	PROL	66695
Propranolol	PPNO	66812
Prostate specific antigen	PSA	66655–66659
Protein—C	PROC	65142, 65171, 65175–65179
Protein—S	PROS	65142, 65171, 65175–65179
Protein, quantitation of—alpha fetoprotein	AFP	66650–66653, 66743, 66750, 66751
Protein, quantitation of—alpha‑l‑antitrypsin	AAT	66635
Protein, quantitation of—beta‑2‑microglobulin	BMIC	66629
Protein, quantitation of—C‑l esterase inhibitor	CEI	66644
Protein, quantitation of—caeruloplasmin	CPLS	66632
Protein, quantitation of—classes or presence and amount of paraprotein by electrophoresis	EPPI	71057, 71058
Protein, quantitation of—ferritin (see also Iron studies)	FERR	66593
Protein, quantitation of—for Down’s syndrome and neural tube defect testing	NTDD	66750, 66751
Protein, quantitation of—haptoglobins	HGLB	66632
Protein, quantitation of—microalbumin	MALB	66560
Protein, total—quantitation of	PROT	66500
Proteus OX 19—microbial antibody testing	POX	69384
Proteus OXK—microbial antibody testing	POK	69384
Prothrombin gene mutation	PGM	73308, 73311
Prothrombin time	PT	65120
Pyruvate	PVTE	66500
Q fever—microbial antibody testing	QFF	69384
Quinalbarbitone	QUIB	66812
Quinidine	QUIN	66800
Quinine	QNN	66812
Rapid plasma reagin test—microbial antibody testing	RPR	69384
RAST	RAST	71079
Rectum—microscopy and culture of material from	MCGR	69312
Red blood cells—Kleihauer	KLEI	65162
Red cell porphyrins—qualitative test	RCP	66782
Referred specimen fee		73940
Renin	REN	66695
Reptilase test	REPT	65120
Respiratory syncytial virus—microbial antibody testing	RSV	69384
Respiratory syncytial virus—microbial antigen testing	RSVN	69494
Reticulin—tissue antigens—antibodies	RCA	71119
Reticulocyte count	RETC	65072
Rheumatoid factor	RF	71106
Rheumatoid factor—quantitation	RFQ	71106
Ross River virus—microbial antibody testing	RRV	69384
RSV (respiratory syncytial virus)—microbial antibody testing	RSV	69384
RSV (respiratory syncytial virus)—microbial antigen testing	RSVN	69494
Rubella—serology	RUB	69384
Salicylate (aspirin)	SALI	66800
Salivary gland—tissue antigens—antibodies	ASG	71165
Salmonella typhi (H)—microbial antibody testing	SAH	69384
Salmonella typhi (O)—microbial antibody testing	SAO	69384
Schistosoma—microbial antibody testing	STO	69384
Scl‑70—tissue antigens—antibodies	SCL	71119
Selenium	SE	66819, 66822
Semen examination	SEE	73523
Semen examination—for spermatozoa (post vasectomy)	SES	73521
Serology—in pregnancy (see Pregnancy serology)
Serotonin	5HT	66779
Serum—B12	B12	66838
Serum—folate	SF	66840
Sex hormone binding globulin	SHBG	66695
Skeletal muscle—tissue antigens—antibodies	SLA	71165
Skin—cytology	SMCY	73043
Skin—microscopy and culture of material from	MCSS	69306
Skin—microscopy, culture and Chlamydia of material from	MCSK	69309
Skin basement membrane—tissue antigens—antibodies	SKA	71165
Smooth muscle—tissue antigens—antibodies	SMA	71119
Snake venom	HISS	66623
Sodium	NA	66500
Solid tissue or tissues—chemical assays	ENZS	66683
Solid tissue or tissues—cytology of fine needle aspiration	FNCY	73049
Solid tissue or tissues—cytology of fine needle aspiration by, or in presence of pathologist	FNCP	73051
Somatomedin	SOMA	66695
Sotalol	SALL	66812
Specific IgE or IgG antibodies	RAST	71079
Specimen referred fee		73940
Sperm antibodies	SAB	73525
Sperm antibodies—penetrating ability	SPA	73525
Sputum—cytology—one specimen	BFCY	73045
Sputum—cytology—3 specimens	SPCY	73047
Sputum—for mycobacteria—one specimen	AFB1	69324
Sputum—for mycobacteria—2 specimens	AFB2	69327
Sputum—for mycobacteria—3 specimens	AFB3	69330
Sputum—microscopy and culture of specimens	MCSP	69318
Stelazine	STEL	66812
Steroid fraction or fractions in urine	USF	66695
Streptococcal serology—anti‑DNASE B titre—microbial antibody testing	ADNB	69384
Streptococcal serology—anti‑streptolysin O titre—microbial antibody testing	ASOT	69384
Streptococcus—Group B	STB	69494
Streptococcus pneumoniae—CSF antigens	SPN	69494
Streptococcus pneumoniae—microbial antibody testing	PCC	69384
Streptococcus pneumoniae—microbial antigen testing	SPN	69494
Strontium	SR	66825, 66828
Stypven test	STYP	65120
Sugar water test	SWT	65075
Sulthiame (Ospolot)	SUL	66812
Supplementary testing for Hepatitis C antibodies	HCST	69441
Syphilis serology	STS	69387
Testosterone	TES	66695
Tetanus—microbial antibody testing	TET	69384
Thalassaemia studies	TS	65078
Theophylline	THEO	66800
Thermoactinomyces vulgaris—microbial antibody testing	THE	69384
Thermopolyspora—microbial antibody testing	TPS	69384
Thiopentone	TOPO	66812
Thioridazine	THIO	66812
Throat—microscopy and culture of material from	MCSW	69303
Thrombin time	TT	65120
Thrombophilia testing (see individual thrombophilia tests)
Thyroglobulin	TGL	66650
Thyroglobulin—tissue antigens—antibodies	ATG	71165
Thyroid function tests (including TSH)	TFT	66719
Thyroid microsome—tissue antigens—antibodies	TMA	71165
Thyroid stimulating hormone (if requested on its own, or as a preliminary test to thyroid function testing)	TSH	66716
Thyroid stimulating hormone (if requested with other hormones referred to in item 66695)	TSH	66722–66734
Tissue transglutaminase antibodies	TTG	71163
Tobramycin		66800
Total protein	PROT	66500
Toxocara—microbial antibody testing	TOC	69384
Toxoplasma—microbial antibody testing	TOX	69384
Treponema pallidum haemagglutination test—microbial antibody testing	TPHA	69384
Trichinosis—microbial antibody testing	TOS	69384
Triglycerides	TRIG	66500
Trimipramine	TRIM	66812
Troponin	TROP	66518
Tryptic activity in faeces	TAF	66677
TSH receptor antibody test—tissue antigens—antibodies	TSHA	71165
Tuberculosis	MANT	73811
Tumour markers—CA‑15.3 antigen	CA15	66650
Tumour markers—CA‑19.9 antigen	CA19	66650
Tumour markers—CA‑125 antigen	C125	66650
Tumour markers—carcinoembryonic antigen	CEA	66650
Tumour markers—mammary serum antigen	MSA	66650
Tumour markers—prostate specific antigen	PSA	66656
Tumour markers—prostatic acid phosphatase—one or more fractions	ACP	66656
Tumour markers—thyroglobulin	TGL	66650
Typhus, Weil‑Felix—microbial antibody testing	TYP	69384
Urate	URAT	66500
Urea	U	66500
Urea, electrolytes, creatinine	U&E	66515
Urethra—microscopy and culture of material from	MCGR	69312
Urine—acidification test	UAT	66587
Urine—catalase test	UCAT	73805
Urine—cystine (cysteine)	UCYS	66782
Urine—cytology—on one specimen	BFCY	73045
Urine—cytology—on 3 specimens	SPCY	73047
Urine—haemoglobin	UHB	66782
Urine—microscopy, culture, identification and sensitivity	UMCS	69333
Urine—porphobilinogen	UPG	66782
Urine—porphyrins—qualitative test	UPR	66782
Urine—steroid fraction or fractions	USF	66695
Urine—urobilinogen	UUB	66782
Vagina—cytology on specimens from	CVO	73057
Vagina—microscopy and culture of material from	MCGR	69312
Valproate (Epilim)	VALP	66800
Vancomycin	VAN	66800
Varicella zoster—microbial antibody testing	VCZ	69384
Varicella zoster—microbial antigen testing	VCZN	69494
Vasoactive intestinal peptide	VIP	66695
Vasopressin	ADH	66695
VDRL (Venereal Disease Research Laboratory)—microbial antibody testing	VDRL	69384
Viscosity of blood or plasma	VISC	65060
Vitamins—B12	B12	66838
Vitamins—D	VITD	66833
Vitamins—folate	SF	66840
Vitamins—quantitation of A, B1, B2, B3, B6, C or E	VIT	66605
VMA (see HMMA)
Von Willebrand’s factor	VWF	65150
Von Willebrand’s factor antigen	VWA	65150
Warfarin	WFR	66812
Yersinia enterocolitica—microbial antibody testing	YER	69384
Zinc	ZN	66667–66670

Part 4—Complexity levels for histopathology items

Complexity levels for histopathology items
Specimen type	Complexity level
Adrenal resection, neoplasm	5
Adrenal resection, not neoplasm	4
Anus, all specimens not otherwise specified	3
Anus, neoplasm, biopsy	4
Anus, neoplasm, radical resection	6
Anus, submucosal resection—neoplasm	5
Appendix	3
Artery, all specimens not otherwise specified	3
Artery, biopsy	4
Bartholin’s gland—cyst	3
Bile duct, resection—all specimens	6
Bone—all specimens not otherwise specified	4
Bone, biopsy, curettings or fragments—lesion	5
Bone, biopsy or curettings quantitation—metabolic disease	6
Bone, femoral head	4
Bone marrow, biopsy	4
Bone, resection, neoplasm—all sites and types	6
Brain neoplasm, resection—cerebello‑pontine angle	4
Brain or meninges, biopsy—all lesions	5
Brain or meninges, not neoplasm—temporal lobe	6
Brain or meninges, resection—neoplasm (intracranial)	5
Brain or meninges, resection—not neoplasm	4
Branchial cleft, cyst	4
Breast, excision biopsy, guidewire localisation—non‑palpable lesion	6
Breast, excision biopsy, or radical resection, malignant neoplasm or atypical proliferative disease—all specimen types	6
Breast, incision biopsy or needle biopsy, malignant neoplasm—all specimen types	4
Breast, microdochectomy	6
Breast, orientated wide local excision for carcinoma with margin assessment	7
Breast tissue—all specimens not otherwise specified	4
Bronchus, biopsy	4
Carotid body—neoplasm	5
Cholesteatoma	3
Digits, amputation—not traumatic	4
Digits, amputation—traumatic	2
Ear, middle and inner—not cholesteatoma	4
Endocrine neoplasm—not otherwise specified	5
Extremity, amputation—not otherwise specified	4
Extremity, amputation or disarticulation—neoplasm	6
Eye, conjunctiva—biopsy or pterygium	3
Eye, cornea	4
Eye, enucleation or exenteration—all lesions	6
Eye—not otherwise specified	4
Fallopian tube, biopsy	4
Fallopian tube, ectopic pregnancy	4
Fallopian tube, sterilisation	2
Fetus with dissection	6
Foreskin—new born	2
Foreskin—not new born	3
Gallbladder	3
Gallbladder and porta hepatis‑radical resection	6
Ganglion cyst, all sites	3
Gum or oral mucosa, biopsy	4
Heart—not otherwise specified	5
Heart valve	4
Hernia sac	2
Hydrocele sac	2
Jaw, upper or lower, including bone—radical resection for neoplasm	6
Joint and periarticular tissue, without bone—all specimens	3
Joint tissue, including bone—all specimens	4
Kidney, biopsy including transplant	5
Kidney, nephrectomy transplant	5
Kidney, partial or total nephrectomy—not neoplasm	4
Kidney, partial or total nephrectomy or nephroureterectomy—neoplasm	6
Large bowel, colostomy—stoma	3
Large bowel (including rectum), biopsy—all sites	4
Large bowel (including rectum), biopsy, for confirmation or exclusion of Hirschsprung’s Disease	5
Large bowel (including rectum), polyp	4
Large bowel (including rectum), segmental resection—neoplasm	6
Large bowel (including rectum), submucosal resection—neoplasm	5
Large bowel, segmental resection—colon, not neoplasm	5
Larynx, biopsy	4
Larynx, partial or total resection	5
Larynx, resection with nodes or pharynx or both	6
Lip biopsy—all specimens not mentioned	3
Lip wedge resection or local excision with orientation	4
Liver—all specimens not otherwise specified	5
Liver, hydatid cyst or resection for trauma	4
Liver, total or subtotal hepatectomy—neoplasm	6
Lung, needle or transbronchial biopsy	4
Lung, resection—neoplasm	6
Lung segment, lobar or total resection	6
Lung, wedge biopsy	5
Lymph node, biopsy—all sites	4
Lymph node, biopsy, for lymphoma or lymphoproliferative disorder	5
Lymph nodes, regional resection—all sites	5
Mediastinum mass	5
Muscle, biopsy	6
Nasopharynx or oropharynx, biopsy	4
Nerve, biopsy neuropathy	5
Nerve, neurectomy or removal of neoplasm	4
Nerve—not otherwise specified	3
Nose, mucosal biopsy	4
Nose or sinuses, polyps	3
Odontogenic neoplasm	5
Odontogenic or dental cyst	4
Oesophagus, biopsy	4
Oesophagus, diverticulum	3
Oesophagus, partial or total resection	6
Oesophagus, submucosal resection—neoplasm	5
Omentum, biopsy	4
Ovary with or without tube—neoplasm	5
Ovary with or without tube—not neoplasm	4
Pancreas, biopsy	5
Pancreas, cyst	4
Pancreas, subtotal or total with or without splenectomy	6
Parathyroid gland(s)	4
Penisectomy—simple	4
Penisectomy with node dissection	5
Peritoneum, biopsy	4
Pituitary neoplasm	4
Placenta—not third trimester	4
Placenta—third trimester, abnormal pregnancy or delivery	4
Pleura or pericardium, biopsy or tissue	4
Products of conception, spontaneous or missed abortion	4
Products of conception, termination of pregnancy	3
Prostate—all types of specimen not otherwise specified	4
Prostate, radical prostatectomy or cystoprostatectomy for carcinoma	7
Prostate, radical resection	6
Retroperitoneum, neoplasm	5
Salivary gland—all specimens not otherwise specified	4
Salivary gland, Mucocele	3
Salivary gland, neoplasm—all sites	5
Sinus, paranasal, biopsy	4
Sinus, paranasal, resection—neoplasm	6
Skin—all specimens not otherwise specified including all neoplasms and cysts	3
Skin, biopsy—blistering skin diseases	4
Skin, biopsy—inflammatory dermatosis	4
Skin, biopsy—investigation of alopecia where serial horizontal sections are taken, except for male pattern baldness	5
Skin, biopsy—investigation of lymphoproliferative disorder	5
Skin, eyelid, wedge resection	4
Skin, local resection—orientation	4
Skin, resection of malignant melanoma or melanoma in situ	5
Small bowel—all specimens not otherwise specified	5
Small bowel—biopsy, all sites	4
Small bowel, diverticulum	3
Small bowel, resection—neoplasm	6
Small bowel, submucosal resection—neoplasm	5
Soft tissue, infiltrative lesion—extensive resections at least 5 cm in maximal dimension	6
Soft tissue, lipoma and variants	3
Soft tissue, neoplasm, not lipoma—all specimens	5
Soft tissue—not otherwise specified	4
Spleen	5
Stomach—all specimens not otherwise specified	4
Stomach, endoscopic biopsy or endoscopic polypectomy	4
Stomach, resection, neoplasm—all specimens	6
Stomach, submucosal resection—neoplasm	5
Tendon or tendon sheath, giant cell neoplasm	4
Tendon or tendon sheath—not otherwise specified	3
Testis and adjacent structures, castration	2
Testis and adjacent structures, neoplasm with or without nodes	5
Testis and adjacent structures—not otherwise specified	3
Testis and adjacent structures, vas deferens sterilisation	2
Testis, biopsy	5
Thymus—not otherwise specified	5
Thyroglossal duct—all lesions	4
Thyroid—all specimens	5
Tissue or organ—all specimens not otherwise specified	3
Tissue or organ not otherwise specified, abscess	3
Tissue or organ not otherwise specified, haematoma	3
Tissue or organ not otherwise specified, malignant neoplasm with regional nodes	6
Tissue or organ not otherwise specified, neoplasm local	4
Tissue or organ not otherwise specified, pilonidal cyst or sinus	3
Tissue or organ not otherwise specified, thrombus or embolus	3
Tissue or organ not otherwise specified, veins varicosity	3
Tongue, biopsy	4
Tongue or tonsil, neoplasm local	5
Tongue or tonsil, neoplasm with nodes	6
Tonsil, biopsy—excluding resection of whole organ	4
Tonsil or adenoids or both	2
Trachea, biopsy	4
Ureter, biopsy	4
Ureter, resection	5
Urethra, biopsy	4
Urethra, resection	5
Urinary bladder—all specimens not otherwise specified	4
Urinary bladder, partial or total with or without prostatectomy	6
Urinary bladder, transurethral resection of neoplasm	5
Uterus and/or cervix—all specimens not otherwise specified	4
Uterus, cervix cone, biopsy (including LEEP or LLETZ biopsy)	5
Uterus, cervix, curettings or biopsy	4
Uterus, endocervix, polyp	3
Uterus, endometrium, polyp	3
Uterus, with or without adnexa, malignant neoplasm—all specimen types not otherwise specified	6
Uterus with or without adnexa, neoplasm, Wertheim’s or pelvic clearance	6
Vagina, biopsy	4
Vaginal mucosa, incidental	3
Vagina, radical resection	6
Vulva or labia, biopsy	4
Vulval, subtotal or total with or without nodes	6

Part 5—Dictionary

Note: All references in the Dictionary to a provision are references to a provision in this Schedule, unless otherwise indicated.

In this Schedule:

abnormal level of TSH, for item 66719, has the meaning given by clause 2.2.5.

Act means the Health Insurance Act 1973.

approved collection centre, for Group P10, has the meaning given by clause 2.10.1.

ASGC, for item 74991, has the meaning given by subclause 2.12.1(3).

biopsy material, for Group P5, has the meaning given by clause 2.5.1.

bulk‑billed, for items 74990 and 74991, has the meaning given by subclause 2.12.1(2).

Commonwealth concession card holder, for items 74990 and 74991, has the meaning given by subclause 2.12.1(2).

compatibility tests by crossmatch, for items 65099 and 65102, has the meaning given by clause 2.1.2.

cytology, for Group P5, has the meaning given by clause 2.5.1.

designated test, has the meaning given by clause 1.2.4.

elevated serum ferritin, for items 73317 and 73318, has the meaning given by clause 2.7.1.

general practitioner, has the meaning given by clause 1.2.6.

group, for a group in this table, means every item in the group.

Hepatitis C sero‑positive, for items 69499 and 69500, has the meaning given by clause 2.3.5.

institution, for Group P10, has the meaning given by clause 2.10.1.

item means:

(a) an item mentioned, by number, in column 1 of a table in:

(i) this Schedule; or

(ii) the diagnostic imaging services table; or

(iii) the general medical services table; or

(b) in a reference immediately followed by a number—the item so numbered.

metal toxicity testing group, has the meaning given by clause 2.2.7.

nutritional metals testing group, has the meaning given by clause 2.2.7.

patient episode means:

(a) a pathology service or pathology services (other than a pathology service to which paragraph (b) refers) provided for a single patient whose need for the service or services was determined under section 16A of the Act:

(i) on the same day; or

(ii) if more than one test is performed on the one specimen within 14 days—on the same or different days;

whether the services:

(iii) are requested by one or more practitioners, participating midwives or participating nurse practitioners; or

(iv) are described in a single item or in more than one item; or

(v) are rendered by one approved pathology practitioner or more than one approved pathology practitioner; or

(vi) are rendered on the same or different days; or

(b) a pathology service to which clause 1.2.3, 2.1.1 or 2.2.2 refers that is provided in the circumstances, set out in the clause, that relate to the service.

Pharmaceutical Benefits Scheme means the scheme for the supply of pharmaceutical benefits established under Part VII of the National Health Act 1953.

practice location, for item 74991, has the meaning given by subclause 2.12.1(3).

prescribed laboratory, for Group P10, has the meaning given by clause 2.10.1.

receiving APP, for a patient episode, means an approved pathology practitioner in an approved pathology authority who:

(a) receives a request from a referring APP to render a designated test or tests; and

(b) renders each test included in the designated test that the referring APP has not performed.

recognised pathologist means:

(a) a medical practitioner recognised as a specialist in pathology under subsection 3D(1) of the Act; or

(b) a medical practitioner in relation to whom there is in force a determination under paragraph 3DB(4)(a) or subsection 3E(1) of the Act that the practitioner is recognised as a specialist in pathology.

referring APP, for a patient episode, means an approved pathology practitioner in an approved pathology authority who:

(a) has received a request to render one or more designated tests; and

(b) is unable, because of the lack of facilities in, or expertise or experience of the staff of, the laboratory of the authority, to render one or more of the tests included in the designated test; and

(i) the test or tests that the approved pathology practitioner is unable to render; or

(ii) all of the tests that are included in the designated test; and

(d) renders each test included in the designated test, other than the test or tests for which the request mentioned in paragraph (c) is made.

regional, rural or remote area, for item 74991, has the meaning given by subclause 2.12.1(3).

request, received by an approved pathology practitioner, includes a request for a pathologist‑determinable service to which subsection 16A(6) of the Act applies.

residential care facility, for Group P10, has the meaning given by clause 2.10.1.

rule 3 exemption means the exemption that has effect because of the operation of clause 1.2.2.

separately identified specimen, for Group P5, has the meaning given by clause 2.5.1.

serial examinations means a series of examinations requested on one occasion, whether or not:

(a) the materials are received on different days by the approved pathology practitioner; or

(b) the examinations or cultures were requested on one or more request forms by the treating practitioner.

serial examinations or cultures, for Group P3, has the meaning given by clause 2.3.1.

serological status is uncertain, for items 69499 and 69500, has the meaning given by clause 2.3.5.

set of pathology services, has the meaning given by clause 1.2.7.

SLA, for item 74991, has the meaning given by subclause 2.12.1(3).

specimen collection centre, for Group P10, has the meaning given by clause 2.10.1.

SSD for item 74991, has the meaning given by subclause 2.12.1(3).

treating practitioner, for Group P10, has the meaning given by clause 2.10.1.

unreferred service, for items 74990 and 74991, has the meaning given by subclause 2.12.1(3).